Patent Application
20230126159
The contents of the electronic sequence listing (EB2021-06b_amended.xml; Size:58,457 bytes; and Date of Creation: Nov. 10, 2022) is herein incorporated by reference in its entirety.
The present invention concerns methods to modulate the level of or modify a target molecule in a subject or an environment.
Microbiomes, in particular within subjects, are constituted of numerous bacterial species that are most of the time beneficial to the subject.
This is the case of the intestinal microbiota, which play a critical role in many instances such as the maturation and continued education of the host immune response (Fulde et al. (2014) Immunol. Rev. 260:21-34); provide protection against pathogen overgrowth (Kamada et al. (2013) Nat. Immunol 14:685-690); influence host-cell proliferation (Ijssennagger et al. (2015) Proc. Natl. Acad. Sci. USA 112:10038-43) and vascularization (Reinhardt et al. (2012) Nature 483:627-631); regulate intestinal endocrine functions (Neuman et al. (2015) FEMS Miicrobiol. Rev. 39:509-521), neurologic signaling (Yano et al. (2015) Cell 161 :264-76), and bone density (Cho et al. (2012) Nature 488:621-6); provide a source of energy biogenesis (Canfora et al. (2015) Nat. Rev. Endocrinol. 11:577-591) (5 to 10% of daily host energy requirements); biosynthesize vitamins (Yatsunenko et al. (2012) Nature 486:222-7), neurotransmitters (Yano et al. (2015) Cell 161:264-76), and multiple other compounds with as yet unknown targets; metabolize bile salts (Devlin et al. (2015) Nat. Chem. Biol. 11:685-690); react to or modify specific drugs; and eliminate exogenous toxins (Haiser et al. (2013) Science 341:295-8).
Similarly, human skin, lung and vagina are home to millions of bacteria that compose the skin microbiota, the lung microbiota and the vaginal microbiota. Similar to those in our gut, skin, lung and vaginal resident microorganisms have essential roles in the protection against invading pathogens (Scharschmidt et al. (2013) Drug Discov. Today Dis. Mech. 10:e83-e89), the education of our immune system (Belkaid et al. (2014) Science 346:954-959) and the breakdown of natural products (Grice (2015) Genome Res. 25:1514-1520), or even the improvement of therapies such as immunotherapies (Dai et al. (2020) Cell Commun Signal. 18(1):90).
In many cases, it can thus be very beneficial to increase the level or potency of the beneficial molecules produced by the microbiome.
However, association studies in humans and rodents have also shown disease-related dysbiosis across a wide spectrum of common chronic disorders, including atherosclerosis, metabolic disorders, asthma, and autism spectrum disorder. Some of these observations have been combined with experimental studies, prospective studies, or both to identify putative microbiota-derived molecular mediators of pathogenic mechanisms. More particularly, some commensal bacteria, in particular some commensal bacterial species or subpopulations of bacterial strains, can produce molecules that are or become harmful for a subject.
Using antibiotics to eliminate these bacteria producing harmful molecules would be either very challenging or dangerous. Indeed, commensal bacteria are strongly engrafted in the host microbiome and belong to a robust community of microorganisms. Having evolved in sometimes a symbiotic relationship, it has been demonstrated that antimicrobial treatment effects on commensal resident bacteria are often only transitory, i.e. the bacteria are repopulating their ecological niche after treatment, or even during treatment by becoming resistant to the treatment. On the other hand, large spectrum antibiotics can sometimes lead to the opposite effect, inducing dysbiosis which is damaging for the subject.
There is thus a need for specifically reducing the level of or deactivating molecules which are harmful for a subject or a subject’s microbiome, or a need for augmenting the level of molecules which are beneficial for a subject or a subject’s microbiome.
Over the past few years, there has been a growing interest in the use of genetically modified bacteria to deliver molecules of therapeutic interest.
While recombinant bacteria are used in industry for the production of insulin or vaccines, researchers are increasingly interested in the direct administration of these recombinant bacteria to humans for either the in situ delivery of proteins of therapeutic interest.
However, most bacteria, after administration, have to compete with resident bacteria of the subject’s microbiome that very often have a strong fitness advantage in their microbiome niche compared to the administered bacterial strain(s). The administered bacteria therefore are often rapidly shed and the ones that remain present in the microbiome are at a too low dose to achieve an effect on the subject or on the subject’s microbiome.
One of the solutions to effectively achieve a sustainable effect on the subject or on the subject’s microbiome, in particular when using bacteria which express a heterologous molecule intended to have a beneficial effect on the subject or on the subject’s microbiome, is to improve or optimize the genetic circuits involved in the production of said heterologous molecule to make them more performant, resulting in higher production of the said heterologous molecule of interest. However, such a solution is not available for all produced molecules and can be detrimental for the administered bacteria by significantly increasing the metabolic burden associated with the production of the molecule, therefore reducing its fitness compared to the resident bacteria, further reducing its colonization potential in the subject’s microbiome. It is therefore still challenging to reach the required level of the heterologous molecule for it to have a beneficial effect in a subject.
There is thus still a need for a solution that can enable bacteria engineered to express heterologous molecules intended to have a beneficial effect in a subject or a subject’s microbiome, to achieve such a real and durable effect.
The present invention meets this need.
The present invention relies on the capacity of specific bacterial strains to advantageously import and metabolize specific sugars, contrary to most strains of a subject’s microbiome, which give them the possibility to stably colonize the subject’s microbiome, when said specific sugars are provided to said subject, at levels unreachable without this competitive advantage.
More particularly, the present invention arises from the unexpected finding by the inventors that it is possible to produce a beneficial molecule at a therapeutically efficient level in a subject, by administering to the subject a probiotic bacterial strain, engineered to produce said beneficial molecule, and which has further been engineered to be able to import and metabolize a rare carbohydrate, which is not or limitedly used by other commensal bacterial strains of the microbiome, and further administering to said subject said rare carbohydrate.
Because these engineered bacterial strains are able to import and metabolize said rare carbohydrate very efficiently, contrary to most other commensal strains of the treated subject’s microbiome, they can reach a colonization level sufficient for producing the beneficial molecule at an overall level which is high enough to lead to a real positive effect in the subject. Moreover, the use of bacterial strains or probiotics as live vectors to deliver biologically active molecules further presents the advantage of combining: (i) the intrinsic beneficial properties of some strains and (ii) the ability to have both a steady and a local production of the protein of interest.
Therefore the present invention concerns a method to modulate the level of or to modify a target molecule in a subject or an environment, said method comprising:
In a particular embodiment, after administration or provision of said engineered bacterial strain and said rare carbohydrate, said engineered bacterial strain is present in the microbiome of said subject or environment at a colonization level enabling an overall production of the molecule of interest in an amount efficient for modulating the level of or modifying the target molecule at a rate leading to an effect on said subject or said environment, or on said subject’s or environment’s microbiome.
In a particular embodiment, after administration or provision of said engineered bacterial strain and said rare carbohydrate, said engineered bacterial strain is present in the microbiome of said subject or environment at a colonization level higher than the natural colonization level of a natural resident bacterial strain of the same species in the microbiome of said subject or environment, during the administration period of the rare carbohydrate and/or of the engineered bacterial strain.
In a particular embodiment, said engineered bacterial strain becomes permanently present. In an alternative embodiment, said engineered bacterial strain becomes temporarily present.
In a particular embodiment, said engineered bacterial strain becomes present at a colonization level corresponding to at least 0.1%, 0.5%, 1%, 2%, 3%, 4% or 5% of the microbiome of the subject. In a particular embodiment, said engineered bacterial strain becomes present at a colonization level corresponding to at least 7%, 10%, 15%, 20% or 25% of the microbiome of the subject.
In a particular embodiment, said method is for reducing the level of a target molecule. In that particular embodiment, said molecule of interest is preferably involved in the degradation, inactivation, adsorption, absorption and/or transport of said target molecule. In still that particular embodiment, said method can be for preventing or treating, in said subject, a disease or a disorder associated with said target molecule.
In an alternative embodiment, said method is for increasing the level of a target molecule. In that particular embodiment, said molecule of interest is preferably involved in the expression, secretion and/or activation of said target molecule, or said molecule of interest is said target molecule. In still that particular embodiment, said method can be for preventing or treating, in said subject, a disease or disorder, a therapy of which comprises said molecule of interest.
In still an alternative embodiment, said method is for modifying a target molecule. In that particular embodiment, said molecule of interest is preferably involved in the phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation and/or lipidation of said target molecule. In still that particular embodiment, said method can be for preventing or treating, in said subject, a disease or disorder associated with said target molecule
In a particular embodiment, said engineered bacterial strain becomes present at a colonization level enabling an overall production of the molecule of interest at a therapeutically or prophylactically efficient amount.
In a particular embodiment, less than 50% of other bacterial cells in the subject or environment utilize the rare carbohydrate as a nutrient source.
In a particular embodiment, the rare carbohydrate is a polysaccharide.
In a particular embodiment, the rare carbohydrate is a sulfated carbohydrate.
In a particular embodiment, the rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans and any combination thereof.
In a particular embodiment, the rare carbohydrate is selected from the group consisting of porphyran, agarose, carrageenan, ulvan, xylan and any combination thereof.
In a particular embodiment, the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
In a particular embodiment, the rare carbohydrate is a sulfated polygalactan.
In a particular embodiment, said heterologous or engineered gene or gene set is or comprises a gene selected from the group consisting of porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
In a particular embodiment, said heterologous or engineered gene or gene set is or comprises a nucleic acid encoding protein(s) which sequence(s) is(are) at least 80% identical to BACPLE_1683-1706 from the Bacteroides plebeius genome.
In a particular embodiment, said heterologous or engineered gene set comprises at least six genes.
In a particular embodiment, the rare carbohydrate is a milk oligosaccharide.
In a particular embodiment, said milk oligosaccharide is a human milk oligosaccharide.
In a particular embodiment, said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
In a particular embodiment, said milk oligosaccharide is selected from the group consisting of fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2′-fucosyllactose, 3′-sialyllactosamine, 3′-fucosyllactose, 3′-sialyl-3-fucosyllactose, 3′-sialyllactose, 6′-sialyllactosamine, 6′-sialyllactose, difucosyllactoase, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and combinations thereof.
In a particular embodiment, said milk oligosaccharide is 2′-fucosyllactose (2FL), lacto-N-triose (LNT), lacto-N-neotetraose (LNnT) or any combination thereof.
In a particular embodiment, said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
In another particular embodiment, said milk oligosaccharide is obtained from human milk.
In a particular embodiment, said engineered bacterial strain comprises at least one gene of the H5 gene cluster from Bifidobacterium longum subsp. infantis.
In a particular embodiment, said engineered bacterial strain is from a species different from Bifidobacterium longum subsp. infantis.
In a particular embodiment, said engineered bacterial strain is from a genera different from Bifidobacterium longum subsp. infantis.
In a particular embodiment, said engineered bacterial strain is a Gram-positive bacterial strain. In a more particular embodiment, said engineered bacterial strain is from the genera Propionibacterium. In a more particular embodiment, said engineered bacterial strain is a Propionibacterium freudenreichii bacteria.
In a particular embodiment, the expression of said heterologous or engineered nucleic acid involved in the expression of said molecule of interest is regulated by said rare carbohydrate. In a more particular embodiment, said heterologous or engineered nucleic acid involved in the expression of said molecule of interest is operably linked to a promoter inducible by the presence of said rare carbohydrate. In still a more particular embodiment, said inducible promoter is not the natural promoter of said heterologous or engineered nucleic acid involved in the expression of said molecule of interest.
The present invention also concerns an engineered bacterial strain comprising (i) a heterologous or engineered nucleic acid involved in the expression of a molecule of interest and (ii) a heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate.
In a particular embodiment, the rare carbohydrate is a polysaccharide.
In a particular embodiment, the rare carbohydrate is a sulfated carbohydrate.
In a particular embodiment, the rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans and any combination thereof.
In a particular embodiment, the rare carbohydrate is selected from the group consisting of porphyran, agarose, carrageenan, ulvan, xylan and any combination thereof.
In a particular embodiment, the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86
In a particular embodiment, the rare carbohydrate is a sulfated polygalactan.
In a particular embodiment, said heterologous or engineered gene or gene set comprises at least one gene selected from the group consisting of porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
In a particular embodiment, said heterologous or engineered gene or gene set comprises at least one nucleic acid encoding proteins which sequence(s) is(are) at least 80% identical to BACPLE_1683-1706 from the Bacteroides plebeius genome.
In a particular embodiment, said heterologous or engineered gene or gene set comprises at least six genes.
In a particular embodiment, the rare carbohydrate is a milk oligosaccharide.
In a particular embodiment, said milk oligosaccharide is a human milk oligosaccharide.
In a particular embodiment, said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
In a particular embodiment, said milk oligosaccharide is selected from the group consisting of fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2′-fucosyllactose, 3′-sialyllactosamine, 3′-fucosyllactose, 3′-sialyl-3-fucosyllactose, 3′-sialyllactose, 6′-sialyllactosamine, 6′-sialyllactose, difucosyllactoase, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and combinations thereof.
In a particular embodiment, said milk oligosaccharide is 2′-fucosyllactose (2FL), lacto-N-triose (LNT), lacto-N-neotetraose (LNnT) or any combination thereof.
In a particular embodiment, said engineered bacterial strain comprises at least one gene of the H5 gene cluster from Bifidobacterium longum subsp, infantis.
In a particular embodiment, said engineered bacterial strain is from a species different from Bifidobacterium longum subsp, infantis.
In a particular embodiment, said engineered bacterial strain is from a genera different from Bifidobacterium longum subsp, infantis.
In a particular embodiment, said engineered bacterial strain is a Gram-positive bacterial strain. In a more particular embodiment, said engineered bacterial strain is from the genera Propionibacterium. In a more particular embodiment, said engineered bacterial strain is a Propionibacterium freudenreichii bacteria.
In a particular embodiment, the expression of said heterologous or engineered nucleic acid involved in the expression of said molecule of interest is regulated by said rare carbohydrate. In a more particular embodiment, said heterologous or engineered nucleic acid involved in the expression of said molecule of interest is operably linked to a promoter inducible by the presence of said rare carbohydrate. In a more particular embodiment, said inducible promoter is not the natural promoter of said heterologous or engineered nucleic acid involved in the expression of said molecule of interest.
In the context of the invention, an engineered bacterial strain comprising a heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is used.
As used herein, the term “engineered” means that the bacterial cell of the invention has been modified by standard molecular biology techniques, typically to introduce the indicated heterologous gene or gene set or to modify the indicated gene or gene set, for example by transformation of the cell with a plasmid, by conjugation, by transduction of the cell with a bacteriophage, or by any suitable technique enabling introducing or modifying a nucleic acid sequence into a bacterial cell. As will be understood by the skilled person, engineering of a bacterial strain implies a deliberate action to introduce or modify a nucleic acid sequence and does not cover introduction or modification of a nucleic acid sequence through natural evolution of the bacterial strain.
For example, the bacteria of the invention can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
Typically, said heterologous gene or gene set involved in the import and/or metabolism of a rare carbohydrate has been incorporated into the bacterial cell’s chromosomal or extrachromosomal expression system, or as extrachromosomal expression system, by genetic engineering techniques known in the art. For example, said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
By “engineered gene or gene set” is meant herein a gene or gene set, autologous to said bacterial strain, but which has been modified by standard molecular biology techniques, typically to introduce a mutation in the sequence of said autologous gene or gene set, in such a way that the expression of the gene or gene set or the activity of the protein encoded by said gene or gene set is modified. As will be understood by the skilled person, engineering of a gene or gene set implies a deliberate action to introduce a modification in the nucleic acid sequence and does not cover mutation of a nucleic acid sequence through natural evolution of the bacterial strain.
Said engineered gene or gene set may be any piece of a gene such as a portion of an open reading frame of a gene, or a sequence involved in the regulation of the expression of a gene such as a promoter, an operator, a terminator. In this specific context, it also encompasses a nucleic acid encoding a transcription factor, a nucleic acid encoding a repressor, a nucleic acid encoding an activator, or a nucleic acid encoding an inducer.
Typically, said engineered gene or gene set providing a competitive advantage has been modified into the bacterial cell’s chromosomal or extrachromosomal expression system, by genetic engineering techniques known in the art. For example, said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
In some embodiments, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is under the control of a high expression promoter. In particular embodiments, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is under the control of an inducible promoter, constitutive promoter, native promoter (e.g., native to the bacterial cell), heterologous promoter, or a promoter associated with said heterologous or engineered gene or gene set in its native form.
The engineered bacterial strain used in the context of the invention can be obtained from any suitable bacterial strain.
As used herein, a “bacterial strain” refers to a genetic variant or subtype within a bacterial species. Therefore, a bacterial strain more particularly refers to a bacterium which remains genetically unchanged when grown or multiplied. The multiplicity of identical bacteria are included. A bacterial strain is typically obtained from the isolation of a clone, which can give birth to a population of cells obtained from a single bacterial cell or colony.
Examples of bacterial strains include, without limitation, strains from bacteria of the genus Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Bordetella spp., Neisseria spp., Aeromonas spp., Franciesella spp., Corynebacterium spp., Citrobacter spp., Chlamydia spp., Hemophilus spp., Brucella spp., Mycobacterium spp., Legionella spp., Rhodococcus spp., Pseudomonas spp., Helicobacter spp., Vibrio spp., Bacillus spp., Erysipelothrix spp., Salmonella spp., Streptomyces spp., Streptococcus spp., Staphylococcus spp., Bacteroides spp., Prevotella spp., Clostridium spp., Bifidobacterium spp., Clostridium spp., Brevibacterium spp., Lactococcus spp., Leuconostoc spp., Actinobacillus spp., Selnomonas spp., Shigella spp., Zymonas spp., Mycoplasma spp., Treponema spp., Leuconostoc spp., Corynebacterium spp., Enterococcus spp., Enterobacter spp., Pyrococcus spp., Serratia spp., Morganella spp., Parvimonas spp., Fusobacterium spp., Actinomyces spp., Porphyromonas spp., Micrococcus spp., Bartonella spp., Borrelia spp., Brucelia spp., Campylobacter spp., Chlamydophilia spp., Cutibacterium spp., Propionibacterium spp., Gardnerella spp., Ehrlichia spp., Haemophilus spp., Leptospira spp., Listeria spp., Mycoplasma spp., Nocardia spp., Rickettsia spp., Ureaplasma spp., Lactobacillus spp. and a mixture thereof.
In some embodiments, bacterial strains used in the context of the invention are anaerobic bacterial strains (e.g., cells that do not require oxygen for growth). Anaerobic bacterial strains include facultative anaerobic strains such as, but not limited to, Escherichia coli, Shewanella oneidensi, Gardnerella vaginalis and Listeria. Anaerobic bacterial strains also include obligate anaerobic strains such as, for example, Bacteroides, Clostridium, Cutibacterium, Propionibacterium, Fusobacterium and Porphyromonas species. In humans, anaerobic bacteria are most commonly found in the gastrointestinal tract. In some particular embodiments, the engineered bacterial strains are thus obtained from bacteria most commonly found in the gastrointestinal tract.
In some embodiments, the bacterial strains are, without limitation, Bacteroides faecis, Bacteroides thetaiotaomicron, Bacteroides fragilis, Bacteroides distasonis, Bacteroides vulgatus, Clostridium leptum, Clostridium coccoides, Staphylococcus aureus, Bacillus subtilis, Clostridium butyricum, Brevibacterium lactofermentum, Streptococcus agalactiae, Lactococcus lactis, Leuconostoc lactis, Actinobacillus actinobycetemcomitans, cyanobacteria, Escherichia coli, Helicobacter pylori, Selenomonas ruminatium, Shigella sonnei, Zymomonas mobilis, Mycoplasma mycoides, Treponema denticola, Bacillus thuringiensis, Staphylococcus lugdunensis, Leuconostoc oenos, Corynebacterium xerosis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus acidophilus, Enterococcus faecalis, Bacillus coagulans, Bacillus cereus, Bacillus popillae, Synechocystis strain PCC6803, Bacillus liquefaciens, Pyrococcus abyssi, Selenomonas nominantium, Lactobacillus hilgardii, Streptococcus ferus, Lactobacillus pentosus, Bacteroides fragilis, Staphylococcus epidermidis, Streptomyces phaechromogenes, Streptomyces ghanaenis, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Morganella morganii, Citrobacter freundii, Propionibacterium freudenreichii, Pseudomonas aeruginosa, Parvimonas micra, Prevotella intermedia, Fusobacterium nucleatum, Prevotella nigrescens, Actinomyces israelii, Porphyromonas endodontalis, Porphyromonas gingivalisMicrococcus luteus, Bacillus megaterium, Aeromonas hydrophila, Aeromonas caviae, Bacillus anthracis, Bartonella henselae, Bartonella Quintana, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Campylobacter coli, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheria, Cutibacterium acnes (formerly Propionibacterium acnes), Ehrlichia canis, Ehrlichia chaffeensis, Enterococcus faecium, Francisella tularensis, Haemophilus influenza, Legionella pneumophila, Leptospira interrogans, Leptospira santarosai, Leptospira weilii, Leptospira noguchii, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumonia, Neisseria gonorrhoeae, Neisseria meningitides, Nocardia asteroids, Rickettsia rickettsia, Salmonella enteritidis, Salmonella typhi, Salmonella paratyphi, Salmonella typhimurium, Shigella flexnerii, Shigella dysenteriae, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Gardnerella vaginalis, Streptococcus viridans, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholera, Vibrio parahaemolyticus, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Actinobacter baumanii, Pseudomonas aeruginosa, and a mixture thereof.
In some embodiments, the bacterial cells are, without limitation, Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Megamonas, Moryella, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira, Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococcus, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter, Weisella, Clostridium, Bacteroides, Ruminococcus, Faecalibacterium, Treponema, Phascolarctobacterium, Megasphaera, Faecalibacterium, Bifidobacterium, Lactobacillus, Sutterella, and/or Prevotella.
In other embodiments, the bacterial strains are, without limitation, Achromobacter xylosoxidans, Acidaminococcus fermentans, Acidaminococcus intestini, Acidaminococcus sp., Acinetobacter baumannii, Acinetobacter junii, Acinetobacter Iwoffii, Actinobacillus capsulatus, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces radingae, Adlercreutzia equolifaciens, Aeromicrobium massiliense, Aggregatibacter actinomycetemcomitans, Akkermansia muciniphila, Aliagarivorans marinus, Alistipes finegoldii, Alistipes indistinctus, Alistipes inops, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Alloscardovia omnicolens, Anaerobacter polyendosporus, Anaerobaculum hydrogeniformans, Anaerococcus hydrogenalis, Anaerococcus prevotii, Anaerococcus senegalensis, Anaerofustis stercorihominis, Anaerostipes caccae, Anaerostipes hadrus, Anaerotruncus colihominis, Aneurinibacillus aneurinilyticus, Bacillus licheniformis, Bacillus massilioanorexius, Bacillus massiliosenegalensis, Bacillus simplex, Bacillus smithii, Bacillus subtilis, Bacillus thuringiensis, Bacillus timonensis, Bacteroides xylanisolvens, Bacteroides acidifaciens, Bacteroides caccae, Bacteroides capillosus, Bacteroides cellulosilyticus, Bacteroides clarus, Bacteroides coprocola, Bacteroides coprophilus, Bacteroides dorei, Bacteroides eggerthii, Bacteroides faecis, Bacteroides finegoldii, Bacteroides fluxus, Bacteroides fragilis, Bacteroides gallinarum, Bacteroides intestinalis, Bacteroides nordii, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides pectinophilus, Bacteroides plebeius, Bacteroides salanitronis, Bacteroides salyersiae, Bacteroides sp., Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Bacteroides pectinophilus ATCC, Barnesiella intestinihominis, Bavariicoccus seileri, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium stercoris, Bilophila wadsworthia, Blautia faecis, Blautia hansenii, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta, Blautia wexlerae, Brachymonas chironomi, Brevibacterium senegalense, Bryantella formatexigens, butyrate-producing bacterium, Butyricicoccus pullicaecorum, Butyricimonas virosa, Butyrivibrio crossotus, Butyrivibrio fibrisolvens, Caldicoprobacter faecalis, Campylobacter concisus, Campylobacter jejuni, Campylobacter upsaliensis, Catenibacterium mitsuokai, Cedecea davisae, Cellulomonas massiliensis, Cetobacterium somerae, Citrobacter braakii, Citrobacter freundii, Citrobacter pasteurii, Citrobacter sp., Citrobacter youngae, Cloacibacillus evryensis, Clostridiales bacterium, Clostridioides difficile, Clostridium asparagiforme, Clostridium bartlettii, Clostridium boliviensis, Clostridium bolteae, Clostridium hathewayi, Clostridium hiranonis, Clostridium hylemonae, Clostridium leptum, Clostridium methylpentosum, Clostridium nexile, Clostridium orbiscindens, Clostridium ramosum, Clostridium scindens, Clostridium sp, Clostridium sp., Clostridium spiroforme, Clostridium sporogenes, Clostridium symbiosum, Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, Collinsella tanakaei, Coprobacillus cateniformis, Coprobacter fastidiosus, Coprococcus catus, Coprococcus comes, Coprococcus eutactus, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium pseudodiphtheriticum, Cutibacterium acnes, Dermabacter hominis, Desulfitobacterium hafniense, Desulfovibrio fairfieldensis, Desulfovibrio piger, Dialister succinatiphilus, Dielma fastidiosa, Dorea formicigenerans, Dorea longicatena, Dysgonomonas capnocytophagoides, Dysgonomonas gadei, Dysgonomonas mossii, Edwardsiella tarda, Eggerthella lenta, Eisenbergiella tayi, Enorma massiliensis, Enterobacter aerogenes, Enterobacter asburiae, Enterobacter cancerogenus, Enterobacter cloacae, Enterobacter massiliensis, Enterococcus casseliflavus, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus sp., Enterovibrio nigricans, Erysipelatoclostridium ramosum, Escherichia coli, Escherichia sp., Eubacterium biforme, Eubacterium dolichum, Eubacterium hallii, Eubacterium limosum, Eubacterium ramulus, Eubacterium rectale, Eubacterium siraeum, Eubacterium ventriosum, Exiguobacterium marinum, Exiguobacterium undae, Faecalibacterium cf, Faecalibacterium prausnitzii, Faecalitalea cylindroides, Ferrimonas balearica, Finegoldia magna, Flavobacterium daejeonense, Flavonifractor plautii, Fusicatenibacter saccharivorans, Fusobacterium gonidiaformans, Fusobacterium mortiferum, Fusobacterium necrophorum, Fusobacterium nucleatum, Fusobacterium periodonticum, Fusobacterium sp., Fusobacterium ulcerans, Fusobacterium varium, Gallibacterium anatis, Gemmiger formicilis, Gordonibacter pamelaeae, Hafnia alvei, Helicobacter bilis, Helicobacter bills, Helicobacter canadensis, Helicobacter canis, Helicobacter cinaedi, Helicobacter macacae, Helicobacter pametensis, Helicobacter pullorum, Helicobacter pylori, Helicobacter rodentium, Helicobacter winghamensis, Herbaspirillum massiliense, Holdemanella biformis, Holdemania filiformis, Holdemania massiliensis, Hungatella hathewayi, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Klebsiella oxytoca, Klebsiella pneumoniae, Kurthia massiliensis, Lachnospira pectinoschiza, Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus animalis, Lactobacillus antri, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus iners, Lactobacillus intestinalis, Lactobacillus johnsonii, Lactobacillus murinus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus ruminis, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Lactobacillus plantarum subsp., Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Listeria grayi, Listeria innocua, Mannheimia granulomatis, Marvinbryantia formatexigens, Megamonas funiformis, Megamonas hypermegale, Methanobrevibacter smithii, Methanobrevibacter smithiiFI, Micrococcus luteus, Microvirgula aerodenitrificans, Mitsuokella jalaludinii, Mitsuokella multacida, Mollicutes bacterium, Murimonas intestini, Neisseria macacae, Nitriliruptor alkaliphilus, Oceanobacillus massiliensis, Odoribacter laneus, Odoribacter splanchnicus, Ornithobacterium rhinotracheale, Oxalobacter formigenes, Paenibacillus barengoltzii, Paenibacillus chitinolyticus, Paenibacillus lautus, Paenibacillus motobuensis, Paenibacillus senegalensis, Paenisporosarcina quisquiliarum, Parabacteroides distasonis, Parabacteroides goldsteinii, Parabacteroides gordonii, Parabacteroides johnsonii, Parabacteroides merdae, Paraprevotella xylaniphila, Parasutterella excrementihominis, Parvimonas micra, Pediococcus acidilactici, Peptoclostridium difficile, Peptoniphilus harei, Peptoniphilus obesi, Peptoniphilus senegalensis, Peptoniphilus timonensis, Phascolarctobacterium succinatutens, Porphyromonas asaccharolytica, Porphyromonas uenonis, Prevotella baroniae, Prevotella bivia, Prevotella copri, Prevotella dentalis, Prevotella micans, Prevotella multisaccharivorax, Prevotella oralis, Prevotella salivae, Prevotella stercorea, Prevotella veroralis, Propionibacterium acnes, Propionibacterium avidum, Propionibacterium freudenreichii, Propionimicrobium lymphophilum, Proteus mirabilis, Proteus penneri ATCC, Providencia alcalifaciens, Providencia rettgeri, Providencia rustigianii, Providencia stuartii, Pseudoflavonifractor capillosus, Pseudomonas aeruginosa, Pseudomonas luteola, Ralstonia pickettii, Rheinheimera perlucida, Rheinheimera texasensis, Riemerella columbina, Romboutsia lituseburensis, Roseburia faecis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus bicirculans, Ruminococcus bromii, Ruminococcus callidus, Ruminococcus champanellensis, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus obeum, Ruminococcus sp, Ruminococcus sp., Ruminococcus torques, Sarcina ventriculi, Sellimonas intestinalis, Senegalimassilia anaerobia, Shigella sonnei, Slackia piriformis, Staphylococcus epidermidis, Staphylococcus lentus, Staphylococcus nepalensis, Staphylococcus pseudintermedius, Staphylococcus xylosus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus caballi, Streptococcus castoreus, Streptococcus didelphis, Streptococcus equinus, Streptococcus gordonii, Streptococcus henryi, Streptococcus hyovaginalis, Streptococcus infantarius, Streptococcus infantis, Streptococcus lutetiensis, Streptococcus merionis, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus ovis, Streptococcus parasanguinis, Streptococcus plurextorum, Streptococcus porci, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sobrinus, Streptococcus thermophilus, Streptococcus thoraltensis, Streptomyces albus, Subdoligranulum variabile, Succinatimonas hippei, Sutterella parvirubra, Sutterella wadsworthensis, Terrisporobacter glycolicus, Terrisporobacter mayombei, Thalassobacillus devorans, Timonella senegalensis, Turicibacter sanguinis, unknown sp, unknown sp., Varibaculum cambriense, Veillonella atypica, Veillonella dispar, Veillonella parvula, Vibrio cincinnatiensis, Virgibacillus salexigens, Weissella paramesenteroides and/or Weissella paramesenteroides ATCC.
In other embodiments, the bacterial strains are those commonly found on the skin microbiota and are without limitation Acetobacter farinalis, Acetobacter malorum, Acetobacter orleanensis, Acetobacter sicerae, Achromobacter anxifer, Achromobacter denitrificans, Achromobacter marplatensis, Achromobacter spanius, Achromobacter xylosoxidans subsp. xylosoxidans, Acidovorax konjaci, Acidovorax radicis, Acinetobacter johnsonii, Actinomadura citrea, Actinomadura coerulea, Actinomadura fibrosa, Actinomadura fulvescens, Actinomadura jiaoheensis, Actinomadura luteofluorescens, Actinomadura mexicana, Actinomadura nitritigenes, Actinomadura verrucosospora, Actinomadura yumaensis, Actinomyces odontolyticus, Actinomycetospora atypica, Actinomycetospora corticicola, Actinomycetospora rhizophila, Actinomycetospora rishiriensis, Aeromonas australiensis, Aeromonas bestiarum, Aeromonas bivalvium, Aeromonas encheleia, Aeromonas eucrenophila, Aeromonas hydrophila subsp, hydrophila, Aeromonas piscicola, Aeromonas popoffii, Aeromonas rivuli, Aeromonas salmonicida subsp, pectinolytica, Aeromonas salmonicida subsp, smithia, Amaricoccus kaplicensis, Amaricoccus veronensis, Aminobacter aganoensis, Aminobacter ciceronei, Aminobacter lissarensis, Aminobacter niigataensis, Ancylobacter polymorphus, Anoxybacillus flavithermus subsp. yunnanensis, Aquamicrobium aerolatum, Archangium gephyra, Archangium gephyra, Archangium minus, Archangium violaceum, Arthrobacter viscosus, Bacillus anthracis, Bacillus australimaris, Bacillus drentensis, Bacillus mycoides, Bacillus pseudomycoides, Bacillus pumilus, Bacillus safensis, Bacillus vallismortis, Bosea thiooxidans, Bradyrhizobium huanghuaihaiense, Bradyrhizobium japonicum, Brevundimonas aurantiaca, Brevundimonas intermedia, Burkholderia aspalathi, Burkholderia choica, Burkholderia cordobensis, Burkholderia diffusa, Burkholderia insulsa, Burkholderia rhynchosiae, Burkholderia terrestris, Burkholderia udeis, Buttiauxella gaviniae, Caenimonas terrae, Capnocytophaga gingivalis, Chitinophaga dinghuensis, Chryseobacterium gleum, Chryseobacterium greenlandense, Chryseobacterium jejuense, Chryseobacterium piscium, Chryseobacterium sediminis, Chryseobacterium tructae, Chryseobacterium ureilyticum, Chryseobacterium vietnamense, Corynebacterium accolens, Corynebacterium afermentans subsp. lipophilum, Corynebacterium minutissimum, Corynebacterium sundsvallense, Cupriavidus metallidurans, Cupriavidus nantongensis, Cupriavidus necator, Cupriavidus pampae, Cupriavidus yeoncheonensis, Curtobacterium flaccumfaciens, Devosia epidermidihirudinis, Devosia riboflavina, Devosia riboflavina, Diaphorobacter oryzae, Dietzia psychralcaliphila, Ensifer adhaerens, Ensifer americanus, Enterococcus malodoratus, Enterococcus pseudoavium, Enterococcus viikkiensis, Enterococcus xiangfangensis, Erwinia rhapontici, Falsirhodobacter halotolerans, Flavobacterium araucananum, Flavobacterium frigidimaris, Gluconobacter frateurii, Gluconobacter thailandicus, Gordonia alkanivorans, Halomonas aquamarina, Halomonas axialensis, Halomonas meridiana, Halomonas olivaria, Halomonas songnenensis, Halomonas variabilis, Herbaspirillum chlorophenolicum, Herbaspirillum frisingense, Herbaspirillum hiltneri, Herbaspirillum huttiense subsp. putei, Herbaspirillum lusitanum, Herminiimonas fonticola, Hydrogenophaga intermedia, Hydrogenophaga pseudoflava, Klebsiella oxytoca, Kosakonia sacchari, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus modestisalitolerans, Lactobacillus plantarum subsp. argentoratensis, Lactobacillus xiangfangensis, Lechevalieria roselyniae, Lentzea albida, Lentzea californiensis, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gelidum subsp. gasicomitatum, Leuconostoc mesenteroides subsp. suionicum, Luteimonas aestuarii, Lysobacter antibioticus, Lysobacter koreensis, Lysobacter oryzae, Magnetospirillum moscoviense, Marinomonas alcarazii, Marinomonas primoryensis, Massilia aurea, Massilia jejuensis, Massilia kyonggiensis, Massilia timonae, Mesorhizobium acaciae, Mesorhizobium qingshengii, Mesorhizobium shonense, Methylobacterium haplocladii, Methylobacterium platani, Methylobacterium pseudosasicola, Methylobacterium zatmanii, Microbacterium oxydan, Micromonospora chaiyaphumensis, Micromonospora chalcea, Micromonospora citrea, Micromonospora coxensis, Micromonospora echinofusca, Micromonospora halophytica, Micromonospora kangleipakensis, Micromonospora maritima, Micromonospora nigra, Micromonospora purpureochromogene, Micromonospora rhizosphaerae, Micromonospora saelicesensis, Microvirga subterranea, Microvirga zambiensis, Mycobacterium alvei, Mycobacterium avium subsp. silvaticum, Mycobacterium colombiense, Mycobacterium conceptionense, Mycobacterium conceptionense, Mycobacterium farcinogenes, Mycobacterium fortuitum subsp. fortuitum, Mycobacterium goodii, Mycobacterium insubricum, Mycobacterium Ilatzerense, Mycobacterium neoaurum, Mycobacterium neworleansense, Mycobacterium obuense, Mycobacterium peregrinum, Mycobacterium saopaulense, Mycobacterium septicum, Mycobacterium setense, Mycobacterium smegmatis, Neisseria subflava, Nocardia lijiangensis, Nocardia thailandica, Novosphingobium barchaimii, Novosphingobium lindaniclasticum, Novosphingobium lindaniclasticum, Novosphingobium mathurense, Ochrobactrum pseudogrignonense, Oxalicibacterium solurbis, Paraburkholderia glathei, Paraburkholderia humi, Paraburkholderia phenazinium, Paraburkholderia phytofirmans, Paraburkholderia sordidicola, Paraburkholderia terricola, Paraburkholderia xenovorans, Paracoccus laeviglucosivorans, Patulibacter ginsengiterrae, Polymorphospora rubra, Porphyrobacter colymbi, Prevotella jejuni, Prevotella melaninogenica, Propionibacterium acnes subsp. elongatum, Proteus vulgaris, Providencia rustigianii, Pseudoalteromonas agarivorans, Pseudoalteromonas atlantica, Pseudoalteromonas paragorgicola, Pseudomonas asplenii, Pseudomonas asuensis, Pseudomonas benzenivorans, Pseudomonas cannabina, Pseudomonas cissicola, Pseudomonas congelans, Pseudomonas costantinii, Pseudomonas ficuserectae, Pseudomonas frederiksbergensis, Pseudomonas graminis, Pseudomonas jessenii, Pseudomonas koreensis, Pseudomonas koreensis, Pseudomonas kunmingensis, Pseudomonas marginalis, Pseudomonas mucidolens, Pseudomonas panacis, Pseudomonas plecoglossicida, Pseudomonas poae, Pseudomonas pseudoalcaligenes, Pseudomonas putida, Pseudomonas reinekei, Pseudomonas rhizosphaerae, Pseudomonas seleniipraecipitans, Pseudomonas umsongensis, Pseudomonas zhaodongensis, Pseudonocardia alaniniphila, Pseudonocardia ammonioxydans, Pseudonocardia autotrophica, Pseudonocardia kongjuensis, Pseudonocardia yunnanensis, Pseudorhodoferax soli, Pseudoxanthomonas daejeonensis, Pseudoxanthomonas indica, Pseudoxanthomonas kaohsiungensis, Psychrobacter aquaticus, Psychrobacter arcticus, Psychrobacter celer, Psychrobacter marincola, Psychrobacter nivimaris, Psychrobacter okhotskensis, Psychrobacter okhotskensis, Psychrobacter piscatorii, Psychrobacter pulmonis, Ramlibacter ginsenosidimutans, Rheinheimera japonica, Rheinheimera muenzenbergensis, Rheinheimera soli, Rheinheimera tangshanensis, Rheinheimera texasensis, Rheinheimera tilapiae, Rhizobium alamii, Rhizobium azibense, Rhizobium binae, Rhizobium daejeonense, Rhizobium endophyticum, Rhizobium etli, Rhizobium fabae, Rhizobium freirei, Rhizobium gallicum, Rhizobium loessense, Rhizobium sophoriradicis, Rhizobium taibaishanense, Rhizobium vallis, Rhizobium vignae, Rhizobium vignae, Rhizobium yanglingense, Rhodococcus baikonurensis, Rhodococcus enclensis, Rhodoferax saidenbachensis, Rickettsia canadensis, Rickettsia heilongjiangensis, Rickettsia honei, Rickettsia raoultii, Roseateles aquatilis, Roseateles aquatilis, Salmonella enterica subsp. salamae, Serratia ficaria, Serratia myotis, Serratia vespertilionis, Shewanella aestuarii, Shewanella decolorationis, Sphingobium amiense, Sphingobium baderi, Sphingobium barthaii, Sphingobium chlorophenolicum, Sphingobium cupriresistens, Sphingobium czechense, Sphingobium fuliginis, Sphingobium indicum, Sphingobium indicum, Sphingobium japonicum, Sphingobium lactosutens, Sphingomonas dokdonensis, Sphingomonas pseudosanguinis, Sphingopyxis chilensis, Sphingopyxis fribergensis, Sphingopyxis granuli, Sphingopyxis indica, Sphingopyxis witflariensis, Staphylococcus agnetis, Staphylococcus aureus subsp. aureus, Staphylococcus epidermidis, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus nepalensis, Staphylococcus saprophyticus subsp. bovis, Staphylococcus sciuri subsp. carnaticus, Streptomyces caeruleatus, Streptomyces canarius, Streptomyces capoamus, Streptomyces ciscaucasicus, Streptomyces griseorubiginosus, Streptomyces olivaceoviridis, Streptomyces panaciradicis, Streptomyces phaeopurpureus, Streptomyces pseudovenezuelae, Streptomyces resistomycificus, Tianweitania sediminis, Tsukamurella paurometabola, Variovorax guangxiensis, Vogesella alkaliphila, Xanthomonas arboricola, Xanthomonas axonopodis, Xanthomonas cassavae, Xanthomonas cucurbitae, Xanthomonas cynarae, Xanthomonas euvesicatoria, Xanthomonas fragariae, Xanthomonas gardneri, Xanthomonas perforans, Xanthomonas pisi, Xanthomonas populi, Xanthomonas vasicola, Xenophilus aerolatus, Yersinia nurmii, Abiotrophia defectiva, Acidocella aminolytica, Acinetobacter guangdongensis, Acinetobacter parvus, Acinetobacter radioresistens, Acinetobacter soli, Acinetobacter variabilis, Actinomyces cardiffensis, Actinomyces dentalis, Actinomyces europaeus, Actinomyces gerencseriae, Actinomyces graevenitzii, Actinomyces haliotis, Actinomyces johnsonii, Actinomyces massiliensis, Actinomyces meyeri, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii subsp. anitratus, Actinomyces odontolyticus, Actinomyces oris, Actinomyces turicensis, Actinomycetospora corticicola, Actinotignum schaalii, Aerococcus christensenii, Aerococcus urinae, Aeromicrobium flavum, Aeromicrobium massiliense, Aeromicrobium tamlense, Aeromonas sharmana, Aggregatibacter aphrophilus, Aggregatibacter segnis, Agrococcus baldri, Albibacter methylovorans, Alcaligenes faecalis subsp. faecalis, Algoriphagus ratkowskyi, Alkalibacterium olivapovliticus, Alkalibacterium pelagium, Alkalibacterium pelagium, Alloprevotella rava, Alsobacter metallidurans, Amaricoccus kaplicensis, Amaricoccus veronensis, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus octavius, Anaerococcus prevotii, Anaerococcus vaginalis, Aquabacterium citratiphilum, Aquabacterium olei, Aquabacterium olei, Aquabacterium parvum, Aquincola tertiaricarbonis, Arcobacter venerupis, Arsenicicoccus bolidensis, Arthrobacter russicus, Asticcacaulis excentricus, Atopobium deltae, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Aureimonas altamirensis, Aureimonas rubiginis, Azospira oryzae, Azospirillum oryzae, Bacillus circulans, Bacillus drentensis, Bacillus fastidiosus, Bacillus lehensis, Bacillus oceanisediminis, Bacillus rhizosphaerae, Bacteriovorax stolpii, Bacteroides coagulans, Bacteroides dorei, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bdellovibrio bacteriovorus, Bdellovibrio exovorus, Belnapia moabensis, Belnapia soli, Blautia hansenii, Blautia obeum, Blautia wexlerae, Bosea lathyri, Brachybacterium fresconis, Brachybacterium muris, Brevibacterium ammoniilyticum, Brevibacterium casei, Brevibacterium epidermidis, Brevibacterium iodinum, Brevibacterium luteolum, Brevibacterium paucivorans, Brevibacterium pityocampae, Brevibacterium sanguinis, Brevundimonas albigilva, Brevundimonas diminuta, Brevundimonas vancanneytii, Caenimonas terrae, Calidifontibacter indicus, Campylobacter concisus, Campylobacter gracilis, Campylobacter hominis, Campylobacter rectus, Campylobacter showae, Campylobacter ureolyticus, Capnocytophaga gingivalis, Capnocytophaga leadbetteri, Capnocytophaga ochracea, Capnocytophaga sputigena, Cardiobacterium hominis, Cardiobacterium valvarum, Camobacterium divergens, Catonella morbi, Caulobacter henricii, Cavicella subterranea, Cellulomonas xylanilytica, Cellvibrio vulgaris, Chitinimonas taiwanensis, Chryseobacterium arachidis, Chryseobacterium daecheongense, Chryseobacterium formosense, Chryseobacterium formosense, Chryseobacterium greenlandense, Chryseobacterium indologenes, Chryseobacterium piscium, Chryseobacterium rigui, Chryseobacterium solani, Chryseobacterium taklimakanense, Chryseobacterium ureilyticum, Chryseobacterium ureilyticum, Chryseobacterium zeae, Chryseomicrobium aureum, Cloacibacterium haliotis, Cloacibacterium normanense, Cloacibacterium normanense, Collinsella aerofaciens, Comamonas denitrificans, Comamonas terrigena, Corynebacterium accolens, Corynebacterium afermentans subsp. lipophilum, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium aurimucosum, Corynebacterium aurimucosum, Corynebacterium coyleae, Corynebacterium durum, Corynebacterium freiburgense, Corynebacterium glaucum, Corynebacterium glyciniphilum, Corynebacterium imitans, Corynebacterium jeikeium, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium massiliense, Corynebacterium mastitidis, Corynebacterium matruchotii, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium mustelae, Corynebacterium mycetoides, Corynebacterium pyruviciproducens, Corynebacterium simulans, Corynebacterium singulare, Corynebacterium sputi, Corynebacterium suicordis, Corynebacterium tuberculostearicum, Corynebacterium tuberculostearicum, Corynebacterium ureicelerivorans, Corynebacterium variabile, Couchioplanes caeruleus subsp. caeruleus, Cupriavidus metallidurans, Curtobacterium herbarum, Dechloromonas agitata, Deinococcus actinosclerus, Deinococcus antarcticus, Deinococcus caeni, Deinococcus ficus, Deinococcus geothermalis, Deinococcus radiodurans, Deinococcus wulumuqiensis, Deinococcus xinjiangensis, Dermabacter hominis, Dermabacter vaginalis, Dermacoccus nishinomiyaensis, Desemzia incerta, Desertibacter roseus, Dialister invisus, Dialister micraerophilus, Dialister propionicifaciens, Dietzia aurantiaca, Dietzia cercidiphylli, Dietzia timorensis, Dietzia timorensis, Dokdonella koreensis, Dokdonella koreensis, Dolosigranulum pigrum, Eikenella corrodens, Elizabethkingia miricola, Elstera litoralis, Empedobacter brevis, Enhydrobacter aerosaccus, Enterobacter xiangfangensis, Enterococcus aquimarinus, Enterococcus faecalis, Enterococcus olivae, Erwinia rhapontici, Eubacterium eligens, Eubacterium infirmum, Eubacterium rectale, Eubacterium saphenum, Eubacterium sulci, Exiguobacterium mexicanum, Facklamia tabacinasalis, Falsirhodobacter halotolerans, Finegoldia magna, Flavobacterium cutihirudinis, Flavobacterium lindanitolerans, Flavobacterium resistens, Friedmanniella capsulata, Fusobacterium nucleatum subsp. polymorphum, Gemella haemolysans, Gemella morbillorum, Gemella palaticanis, Gemella sanguinis, Gemmobacter aquaticus, Gemmobacter caeni, Gordonia jinhuaensis, Gordonia kroppenstedtii, Gordonia polyisoprenivorans, Gordonia polyisoprenivorans, Granulicatella adiacens, Granulicatella elegans, Haemophilus parainfluenzae, Haemophilus sputorum, Halomonas sulfidaeris, Herpetosiphon aurantiacus, Hydrocarboniphaga effusa, Idiomarina maris, Janibacter anophelis, Janibacter hoylei, Janibacter indicus, Janibacter limosus, Janibacter melonis, Jeotgalicoccus halophilus, Jonquetella anthropi, Kaistia geumhonensis, Kingella denitrificans, Kingella oralis, Klebsiella oxytoca, Knoellia aerolata, Knoellia locipacati, Kocuria atrinae, Kocuria carniphila, Kocuria kristinae, Kocuria palustris, Kocuria turfanensis, Lachnoanaerobaculum saburreum, Lachnoanaerobaculum saburreum, Lactobacillus crispatus, Lactobacillus iners, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. lactis, Lactococcus piscium, Lapillicoccus jejuensis, Lautropia mirabilis, Legionella beliardensis, Leptotrichia buccalis, Leptotrichia goodfellowii, Leptotrichia hofstadii, Leptotrichia hongkongensis, Leptotrichia shahii, Leptotrichia trevisanii, Leptotrichia wadei, Luteimonas terricola, Lysinibacillus fusiformis, Lysobacter spongiicola, Lysobacter xinjiangensis, Macrococcus caseolyticus, Marmoricola pocheonensis, Marmoricola scoriae, Massilia alkalitolerans, Massilia alkalitolerans, Massilia aurea, Massilia plicata, Massilia timonae, Megamonas rupellensis, Meiothermus silvanus, Methylobacterium dankookense, Methylobacterium goesingense, Methylobacterium goesingense, Methylobacterium isbiliense, Methylobacterium jeotgali, Methylobacterium oxalidis, Methylobacterium platani, Methylobacterium pseudosasicola, Methyloversatilis universalis, Microbacterium foliorum, Microbacterium hydrothermale, Microbacterium hydrothermale, Microbacterium lacticum, Microbacterium lacticum, Microbacterium laevaniformans, Microbacterium paludicola, Microbacterium petrolearium, Microbacterium phyllosphaerae, Microbacterium resistens, Micrococcus antarcticus, Micrococcus cohnii, Micrococcus flavus, Micrococcus lylae, Micrococcus terreus, Microlunatus aurantiacus, Micropruina glycogenica, Microvirga aerilata, Microvirga aerilata, Microvirga subterranea, Microvirga vignae, Microvirga zambiensis, Microvirgula aerodenitrificans, Mogibacterium timidum, Moraxella atlantae, Moraxella catarrhalis, Morganella morganii subsp. morganii, Morganella psychrotolerans, Murdochiella asaccharolytica, Mycobacterium asiaticum, Mycobacterium chubuense, Mycobacterium crocinum, Mycobacterium gadium, Mycobacterium holsaticum, Mycobacterium iranicum, Mycobacterium longobardum, Mycobacterium neoaurum, Mycobacterium neoaurum, Mycobacterium obuense, Negativicoccus succinicivorans, Neisseria bacilliformis, Neisseria oralis, Neisseria sicca, Neisseria subflava, Nesterenkonia lacusekhoensis, Nesterenkonia rhizosphaerae, Nevskia persephonica, Nevskia ramosa, Niabella yanshanensis, Niveibacterium umoris, Nocardia niwae, Nocardia thailandica, Nocardioides agariphilus, Nocardioides dilutus, Nocardioides ganghwensis, Nocardioides hwasunensis, Nocardioides nanhaiensis, Nocardioides sediminis, Nosocomiicoccus ampullae, Noviherbaspirillum malthae, Novosphingobium lindaniclasticum, Novosphingobium rosa, Ochrobactrum rhizosphaerae, Olsenella uli, Ornithinimicrobium murale, Ornithinimicrobium tianjinense, Oryzobacter terrae, Ottowia beijingensis, Paenalcaligenes suwonensis, Paenibacillus agaridevorans, Paenibacillus phoenicis, Paenibacillus xylanexedens, Paludibacterium yongneupense, Pantoea cypripedii, Parabacteroides distasonis, Paraburkholderia andropogonis, Paracoccus alcaliphilus, Paracoccus angustae, Paracoccus kocurii, Paracoccus laeviglucosivorans, Paracoccus sediminis, Paracoccus sphaerophysae, Paracoccus yeei, Parvimonas micra, Parviterribacter multiflagellatus, Patulibacter ginsengiterrae, Pedobacter aquatilis, Pedobacter ginsengisoli, Pedobacter xixiisoli, Peptococcus niger, Peptoniphilus coxii, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus koenoeneniae, Peptoniphilus lacrimalis, Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Phascolarctobacterium faecium, Phenylobacterium haematophilum, Phenylobacterium kunshanense, Pluralibacter gergoviae, Polymorphobacter multimanifer, Porphyromonas bennonis, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas gingivicanis, Porphyromonas pasteri, Porphyromonas pogonae, Porphyromonas somerae, Povalibacter uvarum, Prevotella aurantiaca, Prevotella baroniae, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella corporis, Prevotella denticola, Prevotella enoeca, Prevotella histicola, Prevotella intermedia, Prevotella jejuni, Prevotella jejuni, Prevotella maculosa, Prevotella melaninogenica, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nanceiensis, Prevotella nigrescens, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella pleuritidis, Prevotella saccharolytica, Prevotella salivae, Prevotella shahii, Prevotella timonensis, Prevotella veroralis, Propionibacterium acidifaciens, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. elongatum, Propionibacterium granulosum, Propionimicrobium lymphophilum, Propionispira arcuata, Pseudokineococcus lusitanus, Pseudomonas aeruginosa, Pseudomonas chengduensis, Pseudonocardia benzenivorans, Pseudorhodoplanes sinuspersici, Psychrobacter sanguinis, Ramlibacter ginsenosidimutans, Rheinheimera aquimaris, Rhizobium alvei, Rhizobium daejeonense, Rhizobium larrymoorei, Rhizobium rhizoryzae, Rhizobium soli, Rhizobium taibaishanense, Rhizobium vignae, Rhodanobacter glycinis, Rhodobacter veldkampii, Rhodococcus enclensis, Rhodococcus fascians, Rhodococcus fascians, Rhodovarius lipocyclicus, Rivicola pingtungensis, Roseburia inulinivorans, Rosenbergiella nectarea, Roseomonas aerilata, Roseomonas aquatica, Roseomonas mucosa, Roseomonas rosea, Roseomonas vinacea, Rothia aeria, Rothia amarae, Rothia dentocariosa, Rothia endophytica, Rothia mucilaginosa, Rothia nasimurium, Rubellimicrobium mesophilum, Rubellimicrobium roseum, Rubrobacter bracarensis, Rudaea cellulosilytica, Ruminococcus gnavus, Runella zeae, Saccharopolyspora rectivirgula, Salinicoccus qingdaonensis, Scardovia wiggsiae, Sediminibacterium ginsengisoli, Selenomonas artemidis, Selenomonas infelix, Selenomonas noxia, Selenomonas sputigena, Shewanella aestuarii, Shuttleworthia satelles, Simonsiella muelleri, Skermanella aerolata, Skermanella stibiiresistens, Slackia exigua, Smaragdicoccus niigatensis, Sneathia sanguinegens, Solirubrobacter soli, Sphingobacterium caeni, Sphingobacterium daejeonense, Sphingobacterium hotanense, Sphingobacterium kyonggiense, Sphingobacterium multivorum, Sphingobacterium nematocida, Sphingobacterium spiritivorum, Sphingobium amiense, Sphingobium indicum, Sphingobium lactosutens, Sphingobium subterraneum, Sphingomonas abaci, Sphingomonas aestuarii, Sphingomonas canadensis, Sphingomonas daechungensis, Sphingomonas dokdonensis, Sphingomonas echinoides, Sphingomonas fonticola, Sphingomonas fonticola, Sphingomonas formosensis, Sphingomonas gei, Sphingomonas hankookensis, Sphingomonas hankookensis, Sphingomonas koreensis, Sphingomonas kyeonggiensis, Sphingomonas laterariae, Sphingomonas mucosissima, Sphingomonas oligophenolica, Sphingomonas pseudosanguinis, Sphingomonas sediminicola, Sphingomonas yantingensis, Sphingomonas yunnanensis, Sphingopyxis indica, Spirosoma rigui, Sporacetigenium mesophilum, Sporocytophaga myxococcoides, Staphylococcus auricularis, Staphylococcus epidermidis, Staphylococcus epidermidis, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus lugdunensis, Staphylococcus pettenkoferi, Stenotrophomonas koreensis, Stenotrophomonas rhizophila, Stenotrophomonas rhizophila, Streptococcus agalactiae, Streptococcus canis, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantis, Streptococcus intermedius, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus sanguinis, Streptomyces iconiensis, Streptomyces yanglinensis, Tabrizicola aquatica, Tahibacter caeni, Tannerella forsythia, Tepidicella xavieri, Tepidimonas fonticaldi, Terracoccus luteus, Tessaracoccus flavescens, Thermus thermophilus, Tianweitania sediminis, Tianweitania sediminis, Treponema amylovorum, Treponema denticola, Treponema lecithinolyticum, Treponema medium, Turicella otitidis, Turicibacter sanguinis, Undibacterium oligocarboniphilum, Undibacterium squillarum, Vagococcus salmoninarum, Varibaculum cambriense, Vibrio metschnikovii, Xanthobacter tagetidis, Xenophilus aerolatus, Xenophilus arseniciresistens, Yimella lutea, Zimmermannella alba, Zimmermannella bifida and/or Zoogloea caeni.
In other embodiments, the bacteria cells are those commonly found in the vaginal microbiota and are, without limitation, Acinetobacter antiviralis, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Actinobaculum massiliense, Actinobaculum schaalii, Actinomyces europaeus, Actinomyces graevenitzii, Actinomyces israelii, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces turicensis, Actinomyces urogenitalis, Actinomyces viscosus, Aerococcus christensenii, Aerococcus urinae, Aerococcus viridans, Aeromonas encheleia, Aeromonas salmonicida, Afipia massiliensis, Agrobacterium tumefaciens, Algoriphagus aquatilis, Aliivibrio wodanis, Alistipes finegoldii,Alloiococcus otitis, Alloprevotella tannerae, Alloscardovia omnicolens, Altererythrobacter epoxidivorans, Ammoniphilus oxalaticus, Amnibacterium kyonggiense, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus obesiensis, Anaerococcus prevotii, Anaerococcus tetradius, Anaerococcus vaginalis, Anaeroglobus geminatus, Anoxybacillus pushchinoensis, Aquabacterium parvum, Arcanobacterium phocae, Arthrobacter aurescens, Asticcacaulis excentricus, Atopobium minutum, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Avibacterium gallinarum, Bacillus acidicola, Bacillus atrophaeus, Bacillus cereus, Bacillus cibi, Bacillus coahuilensis, Bacillus gaemokensis, Bacillus methanolicus, Bacillus oleronius, Bacillus pumilus, Bacillus shackletonii, Bacillus sporothermodurans, Bacillus subtilis, Bacillus wakoensis, Bacillus weihenstephanensis, Bacteroides barnesiae, Bacteroides coagulans, Bacteroides dorei, Bacteroides faecis, Bacteroides forsythus, Bacteroides fragilis, Bacteroides nordii, Bacteroides ovatus, Bacteroides salyersiae, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Bacteroides zoogleoformans, Barnesiella viscericola, Bhargavaea cecembensis, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium dentium, Bifidobacterium longum subsp. infantis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium scardovii, Bilophila wadsworthia, Blautia hydrogenotrophica, Blautia obeum, Blautia producta, Brachybacterium faecium, Bradyrhizobium japonicum, Brevibacterium mcbrellneri, Brevibacterium otitidis, Brevibacterium paucivorans, Bulleidia extructa, Burkholderia fungorum, Burkholderia phenoliruptix, Caldicellulosiruptor saccharolyticus, Caldimonas taiwanensis, Campylobacter gracilis, Campylobacter hominis, Campylobacter sputorum, Campylobacter ureolyticus, Capnocytophaga ochracea, Cardiobacterium hominis, Catonella morbi, Chlamydia trachomatis, Chlamydophila abortus, Chondromyces robustus, Chryseobacterium aquaticum, Citrobacter youngae, Cloacibacterium normanense, Clostridium cavendishii, Clostridium colicanis, Clostridium jejuense, Clostridium perfringens, Clostridium ramosum, Clostridium sordellii, Clostridium viride, Comamonas terrigena, Corynebacterium accolens, Corynebacterium appendicis, Corynebacterium coyleae, Corynebacterium glucuronolyticum, Corynebacterium glutamicum, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium nuruki, Corynebacterium pseudogenitalium, Corynebacterium pyruviciproducens, Corynebacterium singulare, Corynebacterium striatum, Corynebacterium tuberculostearicum, Corynebacterium xerosis, Cryobacterium psychrophilum, Curtobacterium flaccumfaciens, Cutibacterium acnes, Cutibacterium avidum, Cytophaga xylanolytica, Deinococcus radiophilus, Delftia tsuruhatensis, Desulfovibrio desulfuricans, Dialister invisus, Dialister micraerophilus, Dialister pneumosintes, Dialister propionicifaciens, Dickeya chrysanthemi, Dorea longicatena, Eggerthella lenta, Eggerthia catenaformis, Eikenella corrodens, Enhydrobacter aerosaccus, Enterobacter asburiae, Enterobacter cloacae, Enterococcus avium, Enterococcusdurans, Enterococcus faecalis, Enterococcus faecium, Enterococcus hirae, Erwinia persicina, Erwinia rhapontici, Erwinia toletana, Escherichia coli, Escherichia fergusonii, Eubacterium brachy, Eubacterium eligens, Eubacterium nodatum, Eubacterium rectale, Eubacterium saphenum, Eubacterium siraeum, Eubacterium sulci, Eubacterium yurii, Exiguobacterium acetylicum, Facklamia ignava, Faecalibacterium prausnitzii, Filifactor alocis, Finegoldia magna, Fusobacterium gonidiaformans, Fusobacterium nucleatum, Fusobacterium periodonticum, Gardnerella vaginalis, Gemella asaccharolytica, Gemella bergeri, Gemella haemolysans, Gemella sanguinis, Geobacillus stearothermophilus, Geobacillus thermocatenulatus, Geobacillus thermoglucosidasius, Geobacter grbiciae, Granulicatella elegans, Haemophilus ducreyi, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus parainfluenzae, Hafnia alvei, Halomonas meridiana, Halomonas phoceae, Halomonas venusta, Herbaspirillum seropedicae, Janthinobacterium lividum, Jonquetella anthropi, Klebsiella granulomatis, Klebsiella oxytoca, Klebsiella pneumoniae, Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus brevis, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kimchicus, Lactobacillus kitasatonis, Lactobacillus mucosae, Lactobacillus panis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Lactococcus lactis, Leptotrichia buccalis, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc garlicum, Leuconostoc lactis, Leuconostoc mesenteroides, Lysinimonas kribbensis, Mageeibacillus indolicus, Maribacter orientalis, Marinomonas protea, Marinospirillum insulare, Massilia timonae, Megasphaera elsdenii, Megasphaera micronuciformis, Mesorhizobium amorphae, Methylobacterium radiotolerans, Methylotenera versatilis, Microbacterium halophilum, Micrococcus luteus, Microterricola viridarii, Mobiluncus curtisii, Mobiluncus mulieris, Mogibacterium timidum, Moorella glycerini, Moraxella osloensis, Morganella morganii, Moryella indoligenes, Murdochiella asaccharolytica, Mycoplasma alvi, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma muris, Mycoplasma salivarium, Negativicoccus succinicivorans, Neisseria flava, Neisseria gonorrhoeae, Neisseria mucosa, Neisseria subflava, Nevskia ramosa, Nevskia soli, Nitriliruptor alkaliphilus, Odoribacter splanchnicus, Oligella urethralis, Olsenella uli, Paenibacillus amylolyticus, Paenibacillus humicus, Paenibacillus pabuli, Paenibacillus pasadenensis, Paenibacillus pini, Paenibacillus validus, Pantoea agglomerans, Parabacteroides merdae, Paraburkholderia caryophylli, Paracoccus yeei, Parastreptomyces abscessus, Parvimonas micra, Pectobacterium betavasculorum, Pectobacterium carotovorum, Pediococcus acidilactici, Pediococcus ethanolidurans, Pedobacter alluvionis, Pedobacter wanjuense, Pelomonas aquatica, Peptococcus niger, Peptoniphilus asaccharolyticus, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus indolicus, Peptoniphilus lacrimalis, Peptoniphilus massiliensis, Peptostreptococcus anaerobius, Peptostreptococcus massiliae, Peptostreptococcus stomatis, Photobacterium angustum, Photobacterium frigidiphilum, Photobacterium phosphoreum, Porphyromonas asaccharolytica, Porphyromonas bennonis, Porphyromonas catoniae, Porphyromonas endodontalis, Porphyromonasgingivalis, Porphyromonas somerae, Porphyromonas uenonis, Prevotella amnii, Prevotella baroniae, Prevotella bergensis, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella colorans, Prevotella copri, Prevotella corporis, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella intermedia, Prevotella loescheii, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella nigrescens, Prevotella oris, Prevotella pleuritidis, Prevotella ruminicola, Prevotella shahii, Prevotella stercorea, Prevotella timonensis, Prevotella veroralis, Propionimicrobium lymphophilum, Proteus mirabilis, Pseudomonas abietaniphila, Pseudomonas aeruginosa, Pseudomonas amygdali, Pseudomonas azotoformans, Pseudomonas chlororaphis, Pseudomonas cuatrocienegasensis, Pseudomonas fluorescens, Pseudomonas fulva, Pseudomonas lutea, Pseudomonas mucidolens, Pseudomonas oleovorans, Pseudomonas orientalis, Pseudomonas pseudoalcaligenes, Pseudomonas psychrophila, Pseudomonas putida, Pseudomonas synxantha, Pseudomonas syringae, Pseudomonas tolaasii, Pseudopropionibacterium propionicum, Rahnella aquatilis, Ralstonia pickettii, Ralstonia solanacearum, Raoultella planticola, Rhizobacter dauci, Rhizobium etli, Rhodococcus fascians, Rhodopseudomonas palustris, Roseburia intestinalis, Roseburia inulinivorans, Rothia mucilaginosa, Ruminococcus bromii, Ruminococcus gnavus, Ruminococcus torques, Sanguibacter keddieii, Sediminibacterium salmoneum, Selenomonas bovis, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Shewanella algae, Shewanella amazonensis, Shigella boydii, Shigella sonnei, Slackia exigua, Sneathia amnii, Sneathia sanguinegens, Solobacterium moorei, Sorangium cellulosum, Sphingobium amiense, Sphingobium japonicum, Sphingobium yanoikuyae, Sphingomonas wittichii, Sporosarcina aquimarina, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Staphylococcus schleiferi, Staphylococcus simiae, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Stenoxybacter acetivorans, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus equinus, Streptococcus gallolyticus, Streptococcus infantis, Streptococcus intermedius, Streptococcus lutetiensis, Streptococcus marimammalium, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus phocae, Streptococcus pseudopneumoniae, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus thermophilus, Sutterella wadsworthensis, Tannerella forsythia, Terrahaemophilus aromaticivorans, Treponema denticola, Treponema maltophilum, Treponema parvum, Treponema vincentii, Trueperella bernardiae, Turicella otitidis, Ureaplasma parvum, Ureaplasma urealyticum, Varibaculum cambriense, Variovorax paradoxus, Veillonella atypica, Veillonella dispar, Veillonella montpellierensis, Veillonella parvula, Virgibacillus proomii, Viridibacillus arenosi, Viridibacillus arvi, Weissella cibaria, Weissellasoli, Xanthomonas campestris, Xanthomonas vesicatoria, Zobellia laminariae and/or Zoogloea ramigera.
In a particular embodiment, said engineered bacterial strain is from a species different from Bifidobacterium longum subsp. infantis, in a more particular embodiment, said engineered bacterial strain is from a genera different from Bifidobacterium longum subsp. infantis.
In a particular embodiment, said engineered bacterial strain is from a species different from species of the Roseburia genera.
In a particular embodiment said engineered bacterial strain is from a species different from species of the Eubacterium genera.
In a particular embodiment, said engineered bacterial strain is a Gram-positive bacterial strain.
In a more particular embodiment, said engineered bacterial strain is from the genera Propionibacterium.
Examples of Propionibacterium bacteria include Propionibacterium acnes, Propionibacterium avidum, Propionibacterium granulosum, Propionibacterium lymphophilum, Propionibacterium acidipropionici, Propionibacterium freudenreichii, Propionibacterium jensenii and Propionibacterium thoenii.
In a particularly preferred embodiment, said engineered bacterial strain is a Propionibacterium freudenreichii bacteria.
By “gene or gene set involved in the import of a rare carbohydrate” is meant herein a gene or set of genes encoding a molecule enabling directly and/or indirectly the active transport of the rare carbohydrate from the extracellular medium into the cytoplasm.
By “gene or gene set involved in the metabolism of a rare carbohydrate” is meant herein a gene or set of genes encoding a molecule enabling, intracellularly and/or extracellularly after secretion in the extracellular medium or in the periplasm, the degradation of the rare carbohydrate.
In a particular embodiment, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least one gene encoding a transporter of the rare carbohydrate.
In a particular embodiment, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least one gene encoding an intracellular enzyme involved in the degradation of the rare carbohydrate.
In a particularly preferred embodiment, said heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least one gene encoding a transporter of the rare carbohydrate and at least one gene encoding an intracellular enzyme involved in the degradation of the rare carbohydrate.
In a particular embodiment, said heterologous gene or gene set involved in the import and/or metabolism of a rare carbohydrate is from another species than the engineered bacterial strain.
By “rare” carbohydrate is meant herein a carbohydrate that is utilized, as a nutrient source, by less than 50% (e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less than 0.003%, less than 0.001%, less than 0.0001%, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome (i.e., cells “other” than the engineered bacterial strain of the invention, e.g., cells of the resident population prior to administration). Thus, in some embodiments, a rare carbohydrate is one that can be utilized, as a nutrient source, by less than 50% (e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less than 0.003%, less than 0.001 %, less than 0.0001 %, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some cases, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 20% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 2% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 0.5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by none of the other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
In some embodiments, the rare carbohydrate is a polysaccharide.
In some embodiments, the rare carbohydrate is a sulfated carbohydrate. In more particular embodiments, the rare carbohydrate is selected from the group consisting of porphyran, ulvan, carrageenan, fucoidan and any combination thereof.
In some embodiments, the rare carbohydrate is a marine carbohydrate. Examples of marine carbohydrates include but are not limited to: porphyran, agarose, agaropectin, carrageenan, ulvan, alginate, fucoidan, laminarin, and marine microbe exopolysaccharides. In some embodiments, the rare carbohydrate of interest is selected from porphyran and agarose. In some embodiments, the rare carbohydrate is porphyran. In some embodiments, the rare carbohydrate is agarose.
In a particular embodiment, said rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans (such as carrageenan and agarose), porphyran, ulvan, xylan and any combination thereof.
In some embodiments, the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
In some embodiments, the rare carbohydrate is a carbohydrate that contains a glycosidic linkage selected from the group consisting of β-d-galactopyranose to a-l-galactopyranose-6-sulfate, β-d-galactopyranose to 3,6-anhydro-a-l-galactopyranose.
In some embodiments, the rare carbohydrate is a sulfated polygalactan. In some such embodiments, one or more of the galactose residues of the sulfated polygalactan can be a 3,6-anhydro-galactose (e.g., in some embodiments joined by alternating a-1,3 and β-1,4-glycosidic linkage). In some embodiments, one or more of the galactopyranose residues of the sulfated polygalactan can be modified by one or more ester sulfates. In some embodiments, one or more of the galactose residues of the sulfated polygalactan is a 3,6-anhydro-galactose (e.g., in some embodiments joined by alternating a-1,3 and β-1,4-glycosidic linkage); and one or more of the galactopyranose residues of the sulfated polygalactan is modified by one or more ester sulfates.
In a particular embodiment, when the rare carbohydrate is as defined under the section “Polysaccharide” above, the heterologous gene or gene set involved in the import and/or metabolism of a rare carbohydrate can be or comprise a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
In a particular embodiment, when the rare carbohydrate is as defined under the section “Polysaccharide” above, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a gene encoding a porphyranase (e.g., one from GH family 86 (GH86)). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a gene encoding an agarase (e.g., one from GH family 86 (GH86)).
In a particular embodiment, when the rare carbohydrate is as defined under the section “Polysaccharide” above, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1683-1706 from the Bacteroides plebeius genome (or homologs thereof) (see, e.g., Table 1). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1683-1687 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1683-1687 from the B. plebeius genome (or homologs thereof) and BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1683-1699 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding BACPLE_1688-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acid(s) encoding BACPLE_1683-1687 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acid(s) encoding BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acid(s) encoding BACPLE_1683-1687 and BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome (or homologs thereof).
As such, in some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1706 from the B. plebeius genome (see, e.g., Table 1). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1687 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1700-1706 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1687 from the B. plebeius genome (or homologs thereof) and/or at least one of BACPLE_1700-1706 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1688-1706 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1687 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE_1683-1687 and/or at least one of BACPLE_1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE_1688-1699 from the B. plebeius genome.
B. plebeius Homolog ID
In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) and SEQ ID NOs: 28-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 18-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 and SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof).
As such, in some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-34. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-27. In some embodiments, the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 18-34. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21.
In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding (i) at least one protein of sequence selected from SEQ ID NOs: 19, 21 and 22 (or a homolog(s) thereof); (ii) at least one protein of sequence selected from SEQ ID NOs: 26 and 33 (or a homolog(s) thereof); and (iii) at least one protein of sequence selected from SEQ ID NOs: 25 and 32 (or a homolog(s) thereof). In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding proteins of sequences SEQ ID NOs.: 19, 21-22, 25, 26, and 32-33 (or homologs thereof).
In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding (i) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 19, 21 and 22; (ii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 26 and 33; and (iii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 25 and 32. In some embodiments, the heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises nucleic acids encoding proteins having respectively 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with SEQ ID NOs: 19, 21-22, 25, 26, and 32-33.
In some embodiments, said heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least 3 genes (e.g., at least 4, at least 5, at least 6, at least 8 genes, at least 10 genes, at least 12 genes, at least 15 genes, or at least 20 genes). In a particular embodiment, said heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least six genes. In some embodiments, said heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises from 3 to 30 genes (e.g., 5-30, 3-25, 3-20, 3-15, 3-10, 3-8, 5-25, 5-20, 5-15, 5-10, 5-8, 8-30, 8-25, 8-20, 8-15, 10-30, 10-25, 10-20, 10-15, 12-30, 12-25, 12-20, 15-30, 15-25, 20-30, or 20-25 genes). In some embodiments, said heterologous or engineered gene set involved in the import and/or metabolism of a rare carbohydrate comprises 3 to 10 genes.
In a particular embodiment, said rare carbohydrate is a milk oligosaccharide. In a particular embodiment, said milk oligosaccharide can be from any mammalian milk source such as human, bovine, pig, rabbit, goat, sheep or camel milk. In a particular embodiment, said rare carbohydrate is a mammalian milk oligosaccharide (MMO), more particularly a human milk oligosaccharide (HMO).
An “oligosaccharide,” as used herein, refers broadly to a carbohydrate having 3-20 sugar residues or degrees of polymerization from any source.
A “mammalian milk oligosaccharide” or “MMO”, as used herein, refers broadly to an oligosaccharide from mammalian milk, whether it is purified or enriched or detectable in a dairy product, as long as the oligosaccharide is not subject to metabolism by digestive enzymes expressed in the mammalian genome. Therefore, in a particular embodiment, said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
MMO include individual structures synthesized to produce carbohydrate structures known to be in a mammalian milk including milk from human, bovine, equine, porcine, goat, camel, water buffalo, and sheep. It refers broadly to those indigestible glycans, sometimes referred to as “dietary fiber”, or the carbohydrate polymers that are not hydrolyzed by the endogenous mammalian enzymes in the digestive tract (e.g., the small intestine) of the mammal. Mammalian milks contain a significant quantity of MMO that are not usable directly as an energy source for the milk-fed mammal but may be usable by microorganisms in the gut of that mammal.
The core structures of HMO consist of lactose at the reducing ends elongated by β-1-3-linked lacto-N-biose | (LNB, Galβ-3GlcNAc) and/or β-1-3/6-linked N-acetyllactosamine (LacNAc, Galβ1-4GlcNAc). These core structures can be further elongated with residues of galactose (Gal), N-acetylglucosamine (GlcNAc), N-acetylneuraminic acid (Neu5Ac) and decorated with fucose or sialic acid (see Ninonuevo et al. (2006) J Agric Food Chem 54:7471-7480). The combinatorial effect of elongation, fucosylation and sialylation produces a heterogenous mix of short-chain, long-chain and branched structures with more than 200 distinct HMO types identified to date (Kirmiz et al. (2018) Annu Rev Food Sci Technol 9:429). The type 1 tetrasaccharide Lacto-N-tetraose is one of the most highly abundant oligosaccharides in breast milk and together with its isomer Lacto-N-neotetraose (LNnT) and derivatives comprise up to 70% of the total amount of HMO (Ninonuevo et al. (2006) J Agric Food Chem 54:7471-7480).
MMO particularly comprises lacto-N-biose (LNB), lacto-N-triose (LNT), at least one oligosaccharide having a Type I core, at least one oligosaccharide having a Type II core, and/or combinations thereof. Type I or type II may be isomers of each other. MMO typically includes one or more of lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-neotriose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2′-fucosyllactose (2FL), 3′-sialyllactosamine (3SLN), 3′-fucosyllactose (3FL), 3′-sialyl-3-fucosyllactose(3S3FL), 3′-sialyllactose (3SL), 6′-sialyllactosamine (6SLN), 6′-sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N-fucopentaose II (LNFPII), lacto-N-fucopentaose III (LNFPIII), lacto-N-fucopentaose V (LNFPV), sialyllacto-N-tetraose (SLNT), their derivatives, or combinations thereof. Other type II cores include but are not limited to trifucosyllacto-N-hexaose (TFLNH), LNnH, lacto-N-hexaose (LNH), lacto-N-fucopentaose III (LNFPIII), monofucosylated lacto-N-Hexose III (MFLNHIII), Monofucosylmonosialyllacto-N-hexose (MFMSLNH).
In a particular embodiment, said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto-N-neotriose, lacto-N-tetraose, lacto-N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2′-fucosyllactose, 3′-sialyllactosamine, 3′-fucosyllactose, 3′-sialyl-3-fucosyllactose, 3′-sialyllactose, 6′-sialyllactosamine, 6′-sialyllactose, difucosyllactoase, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and combinations thereof.
In a more particular embodiment, said milk oligosaccharide is selected from the group consisting of lacto-N-biose, N-acetyllactosamine, and combinations thereof.
In another particular embodiment, said milk oligosaccharide is selected from 2′-fucosyllactose, lacto-N-triose, lacto-N-neotetrose and combinations thereof.
In a particular embodiment, said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
Modified, recombinant or synthetic milk oligosaccharides can be obtained by any method well-known from the skilled person, in particular by chemical synthesis (as disclosed for example in Bandara et al. (2020) Org Biomol Chem 18(9):1747-1753), biological synthesis or engineering or by fermentation (as disclosed for example in PCT application WO2015/197082).
It has been previously shown that the capacity of a Bifidobacterium bacterial strain to uptake and metabolize human milk oligosaccharides was linked to the presence, in its genome, of a functional H5 cluster.
Therefore, in some embodiments where the rare carbohydrate is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises at least one gene of the H5 gene cluster, in particular at least one gene of a functional H5 gene cluster, from Bifidobacterium longum subsp. infantis.
As used herein, a “functional H5 gene cluster” refers to a cluster of genes in Bifidobacterium responsible for the uptake and metabolism of human milk oligosaccharides containing LNB. A functional H5 cluster typically comprises Blon_2175, Blon_2176 and Blon_2177. The H5 gene cluster typically comprises the following genes: Blon_2171 (which typically encodes a UDP-glucose 4-epimerase, typically a protein of sequence SEQ ID NO: 35), Blon_2173 (which typically encodes an aminoglycoside phosphotransferase, typically a protein of sequence SEQ ID NO: 36), Blon_2174 (which typically encodes a protein of sequence SEQ ID NO: 37), Blon_2175 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 38), Blon_2176 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 39), Blon_2177 (which typically encodes an extracellular solute-binding protein, family 1, typically a protein of sequence SEQ ID NO: 40), and galT (galactose-1-phosphate uridylyltransferase, typically of sequence SEQ ID NO: 41).
Therefore, in some embodiments where the rare carbohydrate is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate comprises at least one gene selected from the group consisting of sequences encoding (i) a protein of sequence SEQ ID NO: 35 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 35, (ii) a protein of sequence SEQ ID NO: 36 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 36, (iii) a protein of sequence SEQ ID NO: 37 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 37, (iv) a protein of sequence SEQ ID NO: 38 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 38, (v) a protein of sequence SEQ ID NO: 39 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 39, (vi) a protein of sequence SEQ ID NO: 40 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 40, and (vii) a protein of sequence SEQ ID NO: 41 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 41.
It has also been shown that bacterial Roseburia or Eubacterium strains were able to uptake and metabolize human milk oligosaccharides, and that this capacity was linked to the presence, in its genome, of a HMO utilization loci, defined by the co-occurrence of GH136 and GH112 genes and the presence of an ABC transporter gene (Pichler et al. (2020). Nat Commun 11:3285).
Therefore, in some embodiments where the rare carbohydrate is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises at least one gene of a Roseburia HMO utilization loci, as defined in Pichler et al. (2020). Nat Commun 11:3285, in particular a Roseburia GH136 gene, a Roseburia GH112 and/or a Roseburia ABC transporter gene.
In other embodiments where the rare carbohydrate is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is or comprises at least one gene of an Eubacterium HMO loci, as defined in Pichler et al. (2020). Nat Commun 11:3285, in particular an Eubacterium GH136 gene, an Eubacterium GH112 and/or an Eubacterium ABC transporter gene.
As used herein, the percent identity is calculated in relation to polymers (e.g., polynucleotide or polypeptide) whose sequences have been aligned. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology=# of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a BLOSUM62 matrix, a BLOSUM30 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In a specific embodiment the BLOSUM30 matrix is used with gap open penalty of 12 and gap extension penalty of 4.
In some embodiments, said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate is under the control of a burden-sensing promoter. More particularly, when said engineered bacterial strain produces a molecule of interest, as defined below, synthesis of said molecule of interest may confer a burden and/or fitness cost on said engineered bacterial strain. In such embodiment, expression of said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate can be up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said heterologous or engineered gene or gene set when said burden-sensing promoter is not induced.
In other embodiments, said engineered bacterial strain further comprises an essential gene operably linked to a burden-sensing promoter, wherein expression of said heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate and/or synthesis of said molecule of interest confer a burden and/or fitness cost on said strain, and wherein expression of said essential gene is up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said essential gene when said burden-sensing promoter is not induced.
Such burden-sensing promoters are typically disclosed in international application WO2021/160854.
Examples of burden-sensing promoters include a σ factor regulated promoter, such as σ32, σB and σS factor regulated promoters, a ribosomal RNA promoter, an HAC1-upregulated promoter comprising a UPR element, and a DNA-damage sensing promoter.
In a particular embodiment, the rare carbohydrate cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate.
In the context of the invention, the method comprises administering the rare carbohydrate, as defined above, to the subject or providing the rare carbohydrate, as defined above, to the environment.
In a particular embodiment, said rare carbohydrate is not used in its natural context. Typically, when the rare carbohydrate is HMO as defined above, the subject is an adult. Indeed, as well-known from the skilled person, HMO are generally not eaten or drunk by adults.
In a particular embodiment, said engineered bacterial strain and said rare carbohydrate are administered either together or separately. For example, the rare carbohydrate may be provided as a solution and the engineered bacterial strain may be provided in dry form or as an enteric-coated tablet or capsule. Alternatively, a composition comprising both the engineered bacterial strain and the rare carbohydrate, for example in the form of a non-aqueous liquid or gel composition or in dry form or as an enteric-coated tablet or capsule, can be administered. Alternatively, the rare carbohydrate may be provided in dry form or as an enteric-coated tablet or capsule and the engineered bacterial strain may be provided in a separate dry form or as an enteric-coated tablet or capsule.
In a particular embodiment, the rare carbohydrate can be administered prior to the administration of the engineered bacterial strain, or the rare carbohydrate can be administered contemporaneously with the administration of the engineered bacterial strain, and/or the rare carbohydrate can be administered after the administration of the engineered bacterial strain.
In a particular embodiment, the rare carbohydrate is administered contemporaneously with the administration of the engineered bacterial strain and further administered after the administration of the engineered bacterial strain.
In a particular embodiment, administering to the subject, or providing the environment, with the rare carbohydrate, as defined above, makes said administered engineered bacterial strain be present in the microbiome of said subject or said environment at a colonization level corresponding to at least 0.5% of the microbiome, in particular of the gut microbiome, of the subject or of the microbiome of the environment, more particularly at least 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20% or at least 25% of the microbiome, in particular of the gut microbiome, of the subject or of the microbiome of the environment.
In another particular embodiment, administering to the subject, or providing the environment, with the rare carbohydrate, as defined above, makes said administered engineered bacterial strain be present in the microbiome of said subject or of said environment at a colonization level higher than the natural colonization level of a natural resident bacterial strain of the same species of the microbiome of said subject or of said environment, during the administration period of the rare carbohydrate.
By “resident species or subspecies of a microbiome” is meant herein the species or subspecies of a microbiome (for example a gut or skin microbiome) which are almost invariably present, and if altered, can be promptly restored, while “transient species or subspecies” can colonize the subject for short periods but tend to be eliminated by competition from the resident microorganisms of the subject’s defense mechanisms.
By “natural resident of a microbiome” is meant herein the species, or subspecies or strains of a microbiome which are almost invariably present in any subject, in the absence of any treatment modifying the composition of the microbiome.
By “natural resident bacterial strain of the same species” is meant herein a natural resident bacterial strain of the same species as the strain from which the engineered bacterial strain of the invention is obtained.
In a more particular embodiment, administering to the subject, or providing the environment, with the rare carbohydrate, as defined above, makes said administered engineered bacterial strain be present in the microbiome of said subject or of said environment at a colonization level higher than the natural colonization level of each natural resident bacterial strain of the same species, as defined above, of the microbiome of said subject or of said environment, during the administration period of the rare carbohydrate.
In a more particular embodiment, administering to the subject, or providing the environment, with the rare carbohydrate, as defined above, makes said administered engineered bacterial strain be present in the microbiome of said subject or of said environment at a colonization level higher than the natural colonization level of a natural resident bacterial subspecies of the same genera, as defined above, of the microbiome of said subject or of said environment, during the administration period of the rare carbohydrate.
By “natural resident bacterial subspecies of the same genera” is meant herein a natural resident bacterial subspecies of the same genera as the strain from which the engineered bacterial strain of the invention is obtained.
In a more particular embodiment, administering to the subject, or providing the environment, with the rare carbohydrate, as defined above, makes said administered engineered bacterial strain be present in the microbiome of said subject or of said environment at a colonization level higher than the natural colonization level of each natural resident bacterial subspecies of the same genera, as defined above, of the microbiome of said subject or of said environment, during the administration period of the rare carbohydrate.
By “natural colonization level” is meant herein the colonization level of a resident strain observed in the microbiome of a subject or environment, in the absence of any treatment affecting the microbiome composition.
In a particular embodiment, said engineered bacterial strain becomes present at a colonization level of 107 cfu / g of wet feces or more, 108 cfu / g of wet feces or more, 109 cfu / g of wet feces or more, or 1010 cfu / g of wet feces or more.
In a particular embodiment, said engineered bacterial strain becomes present at a colonization level as defined above 24 hours after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, or 1 month after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said engineered bacterial strain remains present at a colonization level as defined above (not necessarily at the same level) for 24 hours after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular for 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said colonization level is maintained (not necessarily at the same level) for the whole period during which the engineered bacterial strain and/or the rare carbohydrate is administered, in particular is regularly administered.
In a particular embodiment, said engineered bacterial strain becomes permanently present.
By “permanently present” is meant herein that said engineered bacterial strain remains present in the microbiome of the subject at a detectable level even after stopping administering said rare carbohydrate and said engineered bacterial strain to said subject, in particular at least one month, more particularly at least 3 months, at least 6 months or at least 1 year after after stopping administering said rare carbohydrate and said engineered bacterial strain to said subject.
In an alternative embodiment, said engineered bacterial strain becomes temporarily present.
By “temporarily present” is meant herein that said engineered bacterial strain is not present in the microbiome of the subject at a detectable level 1 week after stopping administering said rare carbohydrate and said engineered bacterial strain to said subject, more particularly 5 days, 4 days, 3 days, 2 days, or one day after stopping administering said rare carbohydrate and said engineered bacterial strain to said subject.
In a particular embodiment, said engineered bacterial strain does not comprise any antibiotic-resistance gene or marker.
In a particular embodiment, said engineered bacterial strain is auxotrophic. In a more particular embodiment, said engineered bacterial strain comprises an auxotrophic selection marker such as alr (alanine racemase), thyA (Thymidylate synthase), dapA (4-hydroxy-tetrahydrodipicolinate synthase). In a more particular embodiment, said engineered bacterial strain is auxotrophic to the nutrient source as defined above.
In a particular embodiment, said engineered bacterial strain further comprises a nucleic acid, in particular a heterologous or engineered nucleic acid, involved in the expression of a molecule of interest, in particular a molecule of interest having a beneficial effect for the subject or environment, or for the subject’s or environment’s microbiome.
In a particular embodiment, the method of the invention further includes administering to the subject or providing to the environment a prebiotic.
Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carrageenan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans- galactooligosaccharide, pectins (e.g., homogalacturonan, citrus pectin, apple pectin, and rhamnogalacturonan-I), dietary fibers (e.g., soy fiber, sugarbeet fiber, pea fiber, corn bran, and oat fiber) and xylooligosaccharides.
In a particular embodiment, said prebiotic is not the rare carbohydrate as defined above.
In the context of the invention, the engineered bacterial strain comprises a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, wherein the expression of said molecule of interest directly or indirectly modulates the level of or modifies the target molecule in said subject or environment.
By “molecule” is meant herein any type of molecule, such as nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, small compounds, metabolites, organic acids, alcohols, etc.. In a particular embodiment, said molecule is a peptide, polypeptide or protein.
When referring to the target molecule, the term “level” means the amount or concentration of said specific target molecule in the subject.
By “modulate” is meant herein directly or indirectly increasing or decreasing the level of the target molecule.
By “modify” is meant herein changing the chemical composition of the target molecule. Examples of modification, in particular of a protein target molecule, include phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation and/or lipidation.
In the context of the invention, said target molecule produces an effect on the subject or on the environment, or on the subject’s or environment’s microbiome.
In a particular embodiment, said target molecule produces a harmful effect on the subject or on the environment, or on the subject’s or environment’s microbiome.
In the context of the invention, by “molecule which produces a harmful effect” is meant herein (i) a molecule which is involved in the triggering and/or the maintenance and/or the progression and/or the worsening of a disease, disorder, or unesthetic aspect in a subject, (ii) a molecule which is responsible for specific symptoms associated with a disease, disorder or unesthetic aspect in a subject, or (iii) a molecule which is responsible for a lack of efficiency of therapeutic and/or prophylactic treatments against a disease or disorder. Examples of such target molecules which produce a harmful effect are disclosed in more detail in the section “Method of preventing or treating a disease, disorder or condition” below.
In the embodiment where said target molecule produces a harmful effect, the method is preferably for reducing the level of said target molecule or for modifying said target molecule. In that particular embodiment, said method can be for preventing or treating, in said subject, a disease or a disorder associated with said target molecule.
By “reduction of the level of the target molecule” is meant herein a decrease in the level of the target molecule after the engineered bacterial strain and the rare carbohydrate are administered compared to the level of said target molecule in the absence of any administration of said engineered bacterial strain and rare carbohydrate.
In a particular embodiment, the reduction of the level of the target molecule is a statistically significant decrease in the level of the target molecule.
In a particular embodiment, said reduction of the level of the target molecule or said modification of the target molecule is observed 30 min after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, or 1 month after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said reduction of the level of the target molecule or said modification of the target molecule is maintained (not necessarily at the same level) for 30 min after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular for 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said reduction of the level of the target molecule or said modification of the target molecule is maintained (not necessarily at the same level) for the whole period during which the engineered bacterial strain and/or the rare carbohydrate is administered, in particular is regularly administered.
In the context of the invention, the reduction of the level of the target molecule or the modification of the target molecule by administration of the engineered bacterial strain is due to the fact that the engineered bacterial strain becomes present in said subject or environment at a colonization level enabling an overall production of the molecule of interest in an amount efficient for reducing the level of or modifying the target molecule at a rate leading to a beneficial effect on said subject or said environment, or on said subject’s or environment’s microbiome.
In an alternative embodiment, said target molecule produces a beneficial effect on a subject or environment, or on a subject’s or environment’s microbiome.
In the context of the invention, by “molecule which produces a beneficial effect” is meant herein (i) a molecule which is involved in the maintenance of a good health or a good esthetic aspect in a subject, (ii) a molecule which is involved in the maintenance of a good health of a microbiome, (iii) a molecule which is involved in the treatment or prevention of a disease, disorder or unesthetic aspect in a subject, (iv) a molecule which increases the efficacy of a therapy against a disease, disorder or unesthetic aspect in a subject, or (v) a molecule which prevents the decrease of efficacy of a therapy against a disease, disorder or unesthetic aspect in a subject. Examples of such target molecules which produce a beneficial effect are disclosed in more detail in the section “Method of preventing or treating a disease, disorder or condition” below.
In the embodiment where said target molecule produces a beneficial effect, the method is preferably for increasing the level of a target molecule. In that particular embodiment, said method can be for preventing or treating, in said subject, a disease or disorder, a therapy of which comprises said molecule of interest. Alternatively, in that particular embodiment, said method can be for increasing or maintaining the efficacy of a therapy against a disease or disorder in said subject, wherein the efficacy of said therapy is directly or indirectly modulated by said molecule of interest.
By “increase of the level of the target molecule” is meant herein an augmentation of the level of the target molecule after the engineered bacterial strain and the rare carbohydrate are administered compared to the level of said target molecule in the absence of any administration of said engineered bacterial strain and rare carbohydrate.
In a particular embodiment, the increase of the level of the target molecule is a statistically significant increase of the level of the target molecule.
In a particular embodiment, said increase of the level of the target molecule is observed 30 min after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, or 1 month after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said increase of the level of the target molecule is maintained (not necessarily at the same level) for 30 min after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate, in particular for 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year after the first administration of the engineered bacterial strain and/or the first administration of the rare carbohydrate.
In a particular embodiment, said increase of the level of the target molecule is maintained (not necessarily at the same level) for the whole period during which the engineered bacterial strain and/or the rare carbohydrate is administered, in particular is regularly administered.
In the context of the invention, the increase of the level of the target molecule by administration of the engineered bacterial strain is due to the fact that the engineered bacterial strain becomes present in the microbiome of said subject at a colonization level enabling an overall production of the molecule of interest in an amount efficient for increasing the level of the target molecule at a rate leading to an effect on said subject or said environment, or on said subject’s or environment’s microbiome.
In the context of the invention, the modulation of the level or the modification of the molecule is mediated by the expression of a molecule of interest encoded by an heterologous or engineered nucleic acid, or which expression is regulated by an heterologous or engineered nucleic acid in said engineered bacterial strain.
By “heterologous nucleic acid” is meant herein any piece of a nucleic acid molecule (for example, DNA) which is inserted by artifice into a cell either transiently or permanently, and becomes part of the organism if integrated into the genome or maintained extrachromosomally. Such an heterologous nucleic acid can be at least a portion of an open reading frame of a gene which is partly or entirely heterologous (i.e., foreign) to the engineered bacteria, or may represent an open reading frame or a portion thereof of a gene homologous to an endogenous gene of the engineered bacteria, which portion optionally encodes a polypeptide with substantially the same activity as the corresponding full length polypeptide, e.g., wild-type polypeptide, or at least one activity of the corresponding full length polypeptide. Such an heterologous nucleic acid can alternatively be a sequence involved in the regulation of the expression of a gene such as a promoter, an operator, a terminator, a nucleic acid encoding a transcription factor, a nucleic acid encoding a repressor, a nucleic acid encoding an activator, or a nucleic acid encoding an inducer.
In a particular embodiment, said heterologous nucleic acid is from another strain than the engineered bacterial strain, more particularly from another species, still particularly from another genera, still particularly from another family, still particularly from another order, still particularly from another class, still particularly from another phylum, still particularly from another kingdom than the engineered bacterial strain.
By “engineered nucleic acid” is meant herein a nucleic acid, autologous to said bacterial strain, but which has been modified by standard molecular biology techniques, typically to introduce a mutation in the sequence of said autologous nucleic acid, in such a way that the activity of the nucleic acid or of the protein encoded by said nucleic acid is modified. As will be understood by the skilled person, engineering of a nucleic acid implies a deliberate action to introduce a modification in the nucleic acid sequence and does not cover mutation of a nucleic acid sequence through natural evolution of the bacterial strain.
Said engineered nucleic acid may be any piece of a nucleic acid molecule such as a gene or a portion thereof, a portion of an open reading frame of a gene, or a sequence involved in the regulation of the expression of a gene such as a promoter, an operator, a terminator, a nucleic acid encoding a transcription factor, a nucleic acid encoding a repressor, a nucleic acid encoding an activator, or a nucleic acid encoding an inducer.
By “molecule of interest” is meant any type of molecule, such as nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, small compounds, metabolites, organic acids, alcohols, etc.. In a particular embodiment, said molecule of interest is a protein, in particular an enzyme.
By “expression of a molecule of interest” is meant herein the direct or indirect expression of a molecule of interest. In particular, said molecule of interest can directly be expressed by said heterologous or engineered nucleic acid, and then be secreted, membrane displayed or kept intracellularly by said engineered bacterial strain. Therefore, in a particular embodiment, the molecule of interest is expressed, secreted and/or displayed by the engineered bacterial strain.
As will be understood by the skilled person, the choice of the molecule of interest the expression of which is mediated by the heterologous or engineered nucleic acid comprised by said engineered bacterial strain will depend on the target molecule the level of which is to be modulated or which is to be modified. Examples of such molecules of interest are disclosed in more detail in the section “Method of preventing or treating a disease, disorder or condition” below.
In the embodiment where said method is for reducing the level of a target molecule as defined above, said molecule of interest is preferably involved in the degradation, inactivation, adsorption, absorption and/or transport of said target molecule.
In the embodiment where said method is for increasing the level of a target molecule as defined above, said molecule of interest is preferably involved in the expression, secretion and/or activation of said target molecule, or said molecule of interest is said target molecule or a pro-form of said target molecule.
In the embodiment where said method is for modifying a target molecule as defined above, said molecule of interest is preferably involved in the phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation and/or lipidation of said target molecule.
Without being bound by theory, the modulation or modification of the target molecule by the expressed molecule of interest is due to the fact that the engineered bacterial strain becomes present in said subject or environment at a colonization level enabling an overall production of the molecule of interest in an amount efficient for modulating the level of or modifying the target molecule at a rate leading to a beneficial effect on said subject or said environment, or on said subject’s or environment’s microbiome.
Therefore, in a particular embodiment, said engineered bacterial strain becomes present at a colonization level enabling an overall production of the molecule of interest at a therapeutically or prophylactically efficient amount.
Typically, said heterologous nucleic acid has been incorporated into the bacterial cell’s chromosomal or extrachromosomal expression system, or as extrachromosomal expression system, by genetic engineering techniques known in the art. Typically, said engineered nucleic acid has been modified by genetic engineering techniques known in the art.
In some embodiments, said heterologous or engineered nucleic acid encoding said molecule of interest is under the control of a high expression promoter. In particular embodiments, said heterologous or engineered nucleic acid is under the control of an inducible promoter, constitutive promoter, native promoter (e.g. native to the bacterial cell), heterologous promoter, or a promoter associated with said nucleic acid in its native form.
In a particular embodiment, the expression of the heterologous or engineered nucleic acid is regulated by the presence of said rare carbohydrate in the environment of said engineered bacterial strain. In a more particular embodiment, said heterologous or engineered nucleic acid is operably linked to a promoter inducible by the presence of said rare carbohydrate in the environment of said engineered bacterial strain. In a particular embodiment, said heterologous or engineered nucleic acid is chromosomally integrated after a promoter that is modulated by the presence of said rare carbohydrate in the environment of said engineered bacterial strain.
In still a more particular embodiment, said inducible promoter is not the natural promoter of said heterologous or engineered nucleic acid.
In a more particular embodiment, said heterologous nucleic acid is chromosomally integrated after a promoter that is modulated by the presence of said rare carbohydrate in the environment of said engineered bacterial strain. In such embodiment, said heterologous nucleic acid may replace the gene naturally located after said promoter, or may be integrated upstream or downstream the gene naturally located after said promoter.
In a particular embodiment, said heterologous nucleic acid is chromosomally integrated upstream of a heterologous gene involved in the import and/or metabolism of said rare carbohydrate, in particular as part of a single operon including said heterologous gene involved in the import and/or metabolism of said rare carbohydrate. Such a location of the heterologous nucleic acid is advantageous to prevent loss of function of the heterologous nucleic acid. Indeed, in case the heterologous nucleic acid is not expressed due to a frameshift mutation and/or a point mutation leading to a STOP codon occuring in the heterologous nucleic acid, the downstream heterologous gene involved in the import and/or metabolism of said rare carbohydrate will not be expressed anymore, and the engineered bacterial strain will not be able to import and/or metabolize said rare carbohydrate, thereby losing its competitive advantage.
In a particular embodiment, said heterologous nucleic acid is chromosomally integrated upstream of an autologous essential gene, in particular as part of a single operon including said autologous essential gene. Such a location of the heterologous nucleic acid is advantageous to prevent loss of function of the heterologous nucleic acid. Indeed, in case the heterologous nucleic acid is not expressed due to a frameshift mutation and/or a point mutation leading to a STOP codon occuring in the heterologous nucleic acid, the downstream autologous essential gene will not be expressed anymore, and the engineered bacterial strain will die.
In a particular embodiment, said heterologous or engineered nucleic acid is a promoter inducible by the presence of said rare carbohydrate in the environment of said engineered bacterial strain.
In a particular aspect of the invention, the bacterial strain used in the context of the invention is engineered in situ. In other words, in all the methods of the invention, the method can alternatively comprise:
By “bacterial delivery vehicle” is meant herein any mean that allows the transfer of a payload into a bacterium.
There are several types of delivery vehicle encompassed by the present invention including, without limitation, bacteriophage scaffold, virus scaffold, chemical based delivery vehicle (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), protein-based or peptide-based delivery vehicle, lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell-penetrating peptides) or donor bacteria (conjugation).
Any combination of delivery vehicles is also encompassed by the present invention.
The delivery vehicle can refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.
In some embodiments, the delivery vehicle is the payload as bacteria are naturally competent to take up a payload from the environment on their own.
In a particular embodiment, said bacterial delivery vehicle is a packaged phagemid, said included genes and nucleic acids being located on the phagemid.
The present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated with a target molecule, said method comprising administering to the subject a therapeutically efficient amount of (a) an engineered bacterial strain, as defined above and (b) a rare carbohydrate, as defined above,
The present invention also concerns a composition or combination comprising an engineered bacterial strain and rare carbohydrate for use in a method for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated with a target molecule, wherein said engineered bacterial strain comprises:
The present invention also concerns the use of an engineered bacterial strain and a rare carbohydrate, as defined above, for the manufacture of a medicament or a pharmaceutical combination intended for the prevention and/or the treatment, in a subject, of a disease, disorder or condition directly or indirectly associated with a target molecule, wherein said engineered bacterial strain comprises:
In the context of the invention, a “disease, disorder or condition directly or indirectly associated with a target molecule” is a disease, disorder or condition, the onset and/or maintenance of which is due to the target molecule.
In a particular embodiment, the target molecule is directly or indirectly responsible for the onset and/or the maintenance and/or the progression and/or the worsening of said disease, disorder or condition. In another particular embodiment, the target molecule is directly or indirectly responsible for specific symptoms associated with said disease, disorder or condition.
In another particular embodiment, the target molecule is directly or indirectly responsible for a lack of efficiency of therapeutic and/or prophylactic therapies against said disease, disorder or condition.
In a more particular embodiment, the target molecule is responsible for such a lack of efficiency by direct interaction with said therapeutic and/or prophylactic therapy, for example by quenching, binding, neutralizing, and/or degrading the active molecule of the therapy. In another more particular embodiment, the target molecule is responsible for such a lack of efficiency by indirect interaction with said therapeutic and/or prophylactic therapy, for example by interacting with the cells targeted by the therapy and making them non- or less responsive to the therapy.
In another particular embodiment, the target molecule is directly or indirectly responsible for specific side effects of therapeutic and/or prophylactic therapies against a disease, disorder or condition.
In a particular embodiment, the target molecule is a toxin. In particular, the target molecule may be an exotoxin or an endotoxin. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis.
Examples of toxins include Colibactin of E. coli, Toxin A and other enzymes (e.g., hemolysin, leukotoxin, exfoliative toxin, enterotoxin, and toxic-shock syndrome toxin-1 (TSST-1)) from Staphylococcus aureus (typically as described in Tam and Torres, Microbiol Spectr. 2019 Mar; 7(2)) and fragilysin (Bft) from Enterotoxigenic (ETBF) strains of Bacteroides fragilis, Botulinum neurotoxin, Tetanus toxin, Diphteria toxin, Anthrax toxin, Alpha toxin, Pertussis toxin, Shiga toxin, Heat-stable enterotoxin ( E. coli ST), or any toxin described in Henkel et al., (Toxins from Bacteria in EXS. 2010 ; 100: 1-29).
By “colibactin” is meant herein a secondary metabolite synthetized by the clbA-S genes present in the 54-kb pathogenicity pks island, a genetic island encoding a non-ribosomal peptide synthetase-polyketide synthase (NRPS-PKS) assembly line in Enterobacteriaceae. Colibactin is typically produced as a prodrug moiety that is exported in the periplasm by the efflux pump ClbM and then hydrolyzed by the periplasmic membrane-bound ClbP protein with a peptidase activity, which releases the active colibactin.
In a particular embodiment, said method is for treating and/or preventing colorectal cancer, and said target molecule is fragilysin, in particular produced by Enterotoxigenic Bacteroides fragilis (ETBF).
In a particular embodiment, said method is for treating and/or preventing colorectal cancer, and said target molecule is colibactin, in particular produced by Enterococcus faecalis and/or E. coli.
In a particular embodiment, said target molecule is a virulence factor.
A virulence factor can be any substance produced by a pathogen that alters host-pathogen interaction by increasing the degree of damage done to the host. Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host’s immune response, to facilitate entry to and egress from host cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host. Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, scavenging factors and factors that promote biofilm formation.
Examples of virulence factors include virulence factors encoded by the following E.coli virulence factor genes EHEC-HlyA, fimA, fimF, fimH, neuC, kpsE, sfa, foc, iroN, aer, iha, papC, papGI, papGII, papGIII, hlyC, cnf1, hra, sat, ireA, usp ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aaiC, aatA, TEM, CTX, SHV, csgA, csgB, csgC, csgD, csgE, csgF, csgG, csgH, genes within T1SS, T2SS, T3SS, T4SS, T5SS, T6SS (secretion systems) and blc, virulence factors encoded by the Yersinia pestis virulence factor gene yscF, virulence factors encoded by the Francisella tularensis virulence factor gene fslA, virulence factors encoded by the Bacillus anthracis virulence factor gene pag, virulence factors encoded by the Vibrio cholera virulence factor genes ctxA, ctxB, tcpA and toxT, virulence factors encoded by the Pseudomonas aeruginosa virulence factor genes pyoverdine (e.g., sigma factor pvdS, biosynthetic genes pvdL, pvdl, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF and pchG), and toxins (e.g., exoU, exoS and exoT), virulence factors encoded by the Klebsiella pneumoniae virulence factor genes fimA and cps, virulence factors encoded by the Acinetobacter baumannii virulence factor genes ptk and epsA, virulence factors encoded by the Salmonella enterica Typhi virulence factor genes MIA and ssrB, virulence factors encoded by the Fusobacterium nucleatum virulence factor genes FadA and TIGIT, and virulence factors encoded by the Bacteroides fragilis virulence factor gene bft.
In a particular embodiment, said target molecule is a molecule encoded by a Cutibacterium acnes porphyrins gene, a CAMP-factor (CAMP1, CAMP2, CAMP3, CAMP4), Hyaluronate lyase (HYL-IB/II, HYL-IA), Lipases (GehA, GehB), Haemolysins, Sialidases, Endoglycoceramidases, Endo-β-N-acetylglucosaminidase, Dermatan sulphate adhesin (DsA1, DsA2), Proline-Threonine Repeats (PTRs) or in any virulence factors included on the acne associated genomic loci 1, 2, 3(plasmid), 4 such as a tight adhesion locus (tad), Streptolysin S-associated genes (sag), nonribosomal peptide synthetases (NRPS) as described in Tomida et al. (2013) mBio 4, e00003-13).
In a particular embodiment, in particular in a method for treating and/or preventing gastric cancer, said target molecule is cytotoxin-associated antigen A (CagA) and/or vacuolating cytotoxin (VacA), preferably produced by Helicobacter pylori.
When said target molecule is a toxin or a virulence factor, as disclosed above, the molecule of interest encoded by the heterologous or engineered nucleic acid can typically be a molecule involved in the degradation, inactivation, adsorption, absorption and/or transport of said target molecule.
In a particular embodiment, said method is for treating and/or preventing hyperphenylalaninemia, and said target molecule is phenylalanine. In that embodiment, said heterologous or engineered nucleic acid typically encodes a phenylalanine ammonia lyase (PAL), a phenylalanine transporter and/or an L-amino acid deaminase (LAAD).
In another particular embodiment, said method is for treating and/or preventing disease involving propionate catabolism, and said target molecule is propionyl CoA or methylmalonyl CoA. In that embodiment, said heterologous or engineered nucleic acid typically encodes one or more propionate catabolism enzyme(s), one or more transporter(s) of propionate, and/or one or more exporter(s) of succinate.
In another particular embodiment, said method is for treating and/or preventing a disease associated with excess branched amino acid, such as MSUD, isovaleric acidemia (IV A), propionic acidemia, methylmalonic acidemia, and diabetes ketoacidosis, as well as other diseases, for example, 3-MCC Deficiency, 3-Methylglutaconyl-CoA hydratase Deficiency, HMG-CoA Lyase Deficiency, Acetyl-CoA Carboxylase Deficiency, Malonyl-CoA Decarboxylase Deficiency, short-branched chain acylCoA dehydrogenase deficiency, 2-methyl-3-hydroxybutyric acidemia, beta-ketothiolase deficiency, isobutyryl-CoA dehydrogenase deficiency, HIBCH deficiency, and 3-Hydroxyisobutyric aciduria, and said target molecule is branched amino acid such as leucine, isoleucine, or valine. In that embodiment, said heterologous or engineered nucleic acid typically encodes one or more transporter(s) of a branched chain amino acid, one or more branched chain amino acid binding protein(s), one or more branched chain amino acid catabolism enzyme(s) that are capable of converting a-ketoisocaproate, a-keto-P-methylvalerate, and/or a-ketoisovalerate to isovaleraldehyde, 2-methylbutyraldehyde, and/or isobutyraldehyde, one or more a-ketoacid decarboxylase(s), one or more branched chain amino acid catabolism enzyme(s) that are capable of converting leucine, isoleucine and/or valine to a-ketoisocaproate, a-keto-β-methylvalerate, and/or a-ketoisovalerate, one or more branched chain amino acid deamination enzymes such as a branched chain amino acid dehydrogenase, branched chain amino acid aminotransferase, and amino acid oxidase, leucine dehydrogenase, one or more branched chain amino acid catabolism enzyme(s) that are capable of converting isovaleraldehyde, isobutyraldehyde and/or 2-methylbutyraldehyde to isopentanol, isobutanol, and/or 2-methylbutanol, one or more branched chain amino acid alcohol dehydrogenases, one or more branched chain amino acid catabolism enzyme(s) that are capable of converting isovaleraldehyde, isobutyraldehyde and/or 2-methylbutyraldehyde to isovalerate, isobutyrate, and/or 2-methylbutyrate, or one or more branched chain amino acid aldehyde dehydrogenases.
In a particular embodiment, said method is for preventing and/or treating a disorder in which trimethylamine is detrimental such as a cardiovascular disease, in particular atherosclerosis, or a kidney disease, and said target molecule is trimethylamine. In that embodiment, said heterologous or engineered nucleic acid typically encodes one or more trimethylamine (TMA) catabolism enzyme(s), such as enzymes that catabolize trimethylamine (TMA) and/or trimethylamine N-oxide, and/or one or more transporter(s) of trimethylamine (TMA) and/or trimethylamine N-oxide (TMAO).
In a particular embodiment, said method is for preventing and/or treating a disease, disorder or condition associated with bile salts such as a metabolic disease (in particular diabetes or obesity) or a cardiovascular disease (in particular hypercholesterolemia), and said target molecule is bile salts. In that embodiment, said heterologous or engineered nucleic acid typically encodes a bile salt hydrolase enzyme, and/or one or more 7a-dehydroxylating enzyme(s).
In a particular embodiment, said method is for preventing and/or treating a disorder in which oxalate is detrimental, in particular hyperoxaluria, and said target molecule is oxalate. In that embodiment, said heterologous or engineered nucleic acid typically encodes one or more oxalate catabolism enzymes.
In a particular embodiment, said method is for preventing and/or treating a disease, disorder or condition caused by a toxic molecule, metabolite or other deleterious molecule, such as a chemotherapy-induced diarrhea or gastrointestinal toxicity, a NSAID-induced diarrhea or gastrointestinal toxicity, or heavy metal poisoning, and said target molecule is a chemotherapeutic drug (in particular selected from irinotecan; methotrexate; an antimetabolite such as gemcitabine and cytosine arabinoside; a fluoropyrimidine such as fluorouracil, capecitabine and tegafur/uracil; a multitargeted folinic acid antagonist such as pemetrexed, raltitrexed and gemcitabine; a plant alkaloid; a vinca alkaloid such as vincristine and vinorelbine; a epipodophyllotoxin such as etoposide; a taxane such as paclitaxel and docetaxel; a topoisomerase I inhibitor; a cytotoxic antibiotic; an anthracycline such as doxorubicin, daunorubicin, idarubicin, aclarubicin, and daunomycin; an alkylating agent such as cyclophosphamide; a platinum such as cisplatin, carboplatin, oxaliplatin, and nedaplatin; an antibody such as ipilumumab; an antibody against VEGF such as bevacizumab; a tyrosine-kinase inhibitor; an EGFR inhibitor such as lapatinib and cetuximab; and a metabolite or byproduct thereof), a NSAID (in particular selected from naproxen, indomethacin, ketoprofen, piroxicam, ibuprofen, diclofenac, a COX-2 inhibitor, and a metabolite or byproduct thereof), a heavy metal (in particular elected from aluminum, antimony, arsenic, barium, bismuth, cadmium, chromium, cobalt, copper, gold, iron, lead, lithium, manganese, mercury, nickel, phosphorous, platinum, selenium, silver, thallium, tin, and zinc), or a metabolite or byproduct thereof. In that embodiment, said heterologous or engineered nucleic acid typically encodes a molecule that is capable of detoxifying said deleterious molecule.
In a particular embodiment, the target molecule is a bacterial enzyme.
In a more particular embodiment, the target molecule is a bacterial enzyme targeting a drug administered to the subject to treat and/or prevent a disease, disorder or condition. In the context of the invention, a “bacterial enzyme targeting a drug” encompasses both an enzyme leading to the elimination, deactivation or reactivation of the drug and an enzyme involved in the more general evolution of the drug activity in the subject once administered to said subject.
Said given drug may be selected from the group consisting of Nicardipine· HCI, Risperidone, Tolcapone, Azathioprine, Entacapone, Exemestane, Nimodipine, Capsaicin, Dexamethasone, Ethacrynic Acid, Rifampin (Rifampicin), Sulindac, Vorinostat, Dolasetron, Mycophenolate Mofetil, Zidovudine (3′-Azido-3′-Deoxythymidine), Allopurinol, Betamethasone, Bisacodyl, Estradiol, Famciclovir, Flutamide, Hydrocortisone, Hydrocortisone Acetate, Methylprednisolone, Metronidazole, Nabumetone, Pantoprazole, Prednisolone, Progesterone, Prednisone, Spironolactone, Sulfasalazine, Tinidazole, Fluoxetine·HCI, Misoprostol, Megestrol Acetate, Capecitabine, Chenodiol (Chenodeoxycholic Acid), Clofazimine, Clonazepam, Cortisone Acetate, Dantrolene·Na, Duloxetine, Fludrocortisone Acetate, IIoperidone, Lorazepam, Nilutamide, Nitisinone, Nitrofurantoin, Oxazepam, Paliperidone, Prasugrel, Probenecid, Rifabutin, Sulfamethoxazole, Ursodiol, Omeprazole, Tenatoprazole, Artemisinin, Danazol, Olmesartan medoxomil, Phenazopyridine, Nitrendipine, Racecadrotil, Fenofibrate, Fluphenazine, Telmisartan, Benzbromarone, Oxethazaine, Mefloquine, Quinacrine, Pimozide, Loxapine succinate, Cyclobenzaprine, Ethopropazine, Promethazine, Clemizole and Pyrimethamine.
Said given drug may further be selected from the group consisting of abacavir sulfate, acebutolol, acecainide, alfuzosin, almotriptan, alprenolol, amantadine, aminoglutethimide, amisulpride, anagrelide, anastrozole, antazoline phosphate, apomorphine, artemisinin, atenolol, atorvastatin calcium, azatadine maleate, bambuterol, Benazepril, benzbromarone, benzthiazide, betamethasone acetate, betamethasone valerate, betaxalol, bezafibrate, bicalutamide, biperiden, bisacodyl, bisoprolol fumarate, bromocriptine mesylate, budesonide, bupropion, buramate, buspirone, camylofine dihydrochloride, capecitabine, carbetapentane citrate, carbinoxamine maleate, carisoprodol, Carvedilol, celecoxib, cetirizine, chlormezanone, cimetidine, citalopram hydrobromide, clemastine fumarate, clemizole, clenbuterol, clidinium bromide, clonidine, clopidogrel sulfate, Clozapine, colchicine, cyclobenzaprine, cyclophosphamide, cyproterone acetate, dabigatran etexilate mesylate, danazol, darifenacin hydrobromide, dasatinib, deflazacort, desvenlafaxine succinate, dexamethasone, dextromethorphan hydrobromide, diacetamate, Dicyclomine, diflorasone diacetate, digitoxin, digoxin, diltiazem, diperodon, diphenylpyraline, Dipyridamole, disopyramide phosphate, domperidone, doxazosin mesylate, doxepin, doxylamine succinate, drospirenone, duloxetine, eletriptan hydrobromide, enalapril maleate, Entacapone, ergonovine maleate, ergotamine tartrate, eszopiclone, ethopropazine, ethoxzolamide, ethynodiol diacetate, etodolac, ezetimibe, famciclovir, famprofazone, febuxostat, fenofibrate, fenspiride, fexofenadine, finasteride, fluconazole, fluoxetine, fluphenazine, fluvoxamine maleate, galantamine, gliclazide, glipizide, griseofulvin, guanfacine, haloperidol, hyoscyamine, idebenone, imatinib, indapamide, indomethacin, Irbesartan, irsogladine maleate, isradipine, itraconazole, ketorolac tromethamine, ketotifen fumarate, labetalol, lamotrigine, letrozole, levamisole, levonorgestrel, linagliptin, lofexidine, Loperamide, losartan, lovastatin, loxapine succinate, mebendazole, mebhydrolin naphthalenesulfonate, mefloquine, megestrol acetate, melphalan, memantine, metaxalone, Methocarbamol, methoxsalen, methsuximide, methylphenidate, methysergide maleate, meticrane, metitepine maleate, metoclopramide, metolazone, metoprolol tartrate, mevastatin, mianserin, mifepristone, milnacipran, mycophenolate mofetil, nadolol, nafronyl oxalate, naftopidil, naloxone, naproxen(+), nateglinide, nefazodone, nefopam, neostigmine bromide, nevirapine, nicergoline, nitrendipine, nizatidine, norethindrone acetate, Norgestimate, noscapine, olanzapine, olmesartan medoxomil, omeprazole, orphenadrine citrate, oxaprozin, oxcarbazepine, oxethazaine, oxybutynin chloride, Paclitaxel, paliperidone, pantoprazole, papaverine, paroxetine, penbutolol sulfate, pentoxifylline, pergolide mesylate, pericyazine, perindopril erbumine, phenacetin, Phenazopyridine, phenytoin sodium, pidotimod, pimozide, pitavastatin calcium, Pranoprofen, prazosin, prednisone, pridinol methanesulfonate, primaquine phosphate, Procarbazine, promethazine, pyrimethamine, quetiapine, quinacrine, quinapril, quinine sulfate, racecadotril, ramelteon, ramipril, ranitidine, ranolazine, rebamipide, repaglinide, Reserpine, riluzole, rimantadine, risperidone, ritonavir, rivastigmine tartrate, rizatriptan benzoate, ropinirole, rosiglitazone maleate, rosuvastatin calcium, roxatidine acetate, sertraline, sildenafil citrate, solifenacin succinate, sotalol, spiperone, sulfasalazine, sulfinpyrazone, sulindac, sulpiride, sumatriptan succinate, tacrine, tacrolimus, tadalafil, tamsulosin hydrchloride, tegaserod maleate, telmisartan, tenatoprazole, tenoxicam, terazosin, terbinafine, thiabendazole, thiothixene, tiapride, timolol maleate, tinidazole, Tolazamide, topotecan, trandolapril, tranilast, trazodone, trihexyphenidyl, trimebutine maleate, trimetazidine dihydrochloride, trimethobenzamide, trimipramine maleate, Triprolidine, tropisetron, trospium chloride, valsartan, venlafaxine, verapamil, vilazodone, Vinpocetine, voriconazole, warfarin, zaleplon, zidovudine [azt], ziprasidone mesylate and zolpidem.
In a particular embodiment, said target molecule is selected from the bacterial enzymes having oxidation, deamination, isomerization, esterification, condensation, reduction, hydrolysis and/or rearrangement activities. In a particular embodiment, said target molecule is selected from β-glucuronidases, nitroreductases and sulfoxide reductases.
In a particular embodiment, when said given drug is dantrolene, clonazepam, and/or nicardipine, said target molecule is an enzyme having nitro-reduction activity.
In an alternative embodiment, when said given drug is risperidone, said target molecule is an enzyme having hydrolysis activity, in particular an enzyme hydrolysing the isoxazole moiety of risperidone.
In an alternative embodiment, when said given drug is sulfasalazine, said target molecule is an enzyme having azoreduction activity.
In an alternative embodiment, when said given drug is digoxin, said target molecule is cytochrome glycoside reductase.
In an alternative embodiment, when said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease, said target molecule is tyrosine decarboxylase and/or dopamine dehydrolase.
In another embodiment, when said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease, said target molecule is DHPAA synthase.
In an alternative embodiment, when said given drug is gemcitabine, said molecule is a cytidine deaminase.
In an alternative embodiment, when said given drug is prontosil, said target molecule is an enzyme converting prontosil into p-aminobenzenesulfonamide by azo-reduction.
In an alternative embodiment, when said given drug is selected from sulfasalazine, ipsalazide and balsalazide, said target molecule is an enzyme converting said drug into 5-aminosalicylic acid.
In an alternative embodiment, when said given drug is a non-steroidal anti-inflammatory drug, said target molecule is a β-glucuronidase.
In a particular embodiment, in particular in a method for treating and/or preventing type 2 diabetes, said target molecule is a bacterial enzyme involved in amino acid metabolism.
In a particular embodiment, said target molecule is a bacterial adhesin.
In a more particular embodiment, said target molecule is a bacterial adhesin involved in the adsorption of a given drug, administered to the subject to treat and/or prevent a disease, disorder or condition, to a bacterial strain.
In a particular embodiment, when said given drug is L-DOPA, typically in a subject suffering from Parkinson’s disease, said target molecule is a molecule involved in the adsorption of L-DOPA by Helicobacter pylori, typically a bacterial adhesin from H. pylori involved in said adsorption.
In a particular embodiment, said target molecule is a bacterial molecule competing with a given drug for a receptor of the subject’s cells.
In a particular embodiment, when said given drug is acetaminophen, said target molecule is p-cresol produced by C. difficile or an enzyme involved in the production and/or secretion of p-cresol by C. difficile.
The present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition, a therapy of which comprises a target molecule, said method comprising administering to the subject a therapeutically efficient amount of (a) an engineered bacterial strain, as defined above and (b) a rare carbohydrate, as defined above,
The present invention also concerns a composition or combination comprising an engineered bacterial strain and rare carbohydrate, as defined above, for use in a method for preventing and/or treating, in a subject, a disease, disorder or condition, a therapy of which comprises a target molecule, wherein said engineered bacterial strain comprises:
The present invention also concerns the use of an engineered bacterial strain and a rare carbohydrate, as defined above, for the manufacture of a medicament or a pharmaceutical combination intended for the prevention and/or the treatment, in a subject, of a disease, disorder or condition, a therapy of which comprises a target molecule, wherein said engineered bacterial strain comprises:
In a particular embodiment, said method is for preventing and/or treating a disease, disorder or condition that benefit from reduced gut inflammation and/or tighten gut mucosal barrier, such as an autoimmune disorder (in particular selected from the group consisting of type 1 diabetes, asthma, multiple sclerosis, lupus, rheumatoid arthritis, ulcerative colitis, juvenile arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, celiac disease, and ankylosing spondylitis) or a disease or condition associated with gut inflammation and/or compromised gut barrier function (in particular selected from an inflammatory bowel disease and a diarrheal disease). In that embodiment, said heterologous or engineered nucleic acid typically encodes a non-native, anti-inflammatory molecule, a non-native gut barrier function enhancer molecule and/or a biosynthetic pathway, wherein the final product of the biosynthetic pathway is an anti-inflammatory molecule and/or a gut barrier function enhancer molecule.
In a particular embodiment, said method is for preventing and/or treating a disease, disorder or condition selected from the group consisting of Nonalcoholic Steatohepatitis (NASH), Nonalcoholic fatty liver disease (NAFLD), type 1 diabetes, type 2 diabetes, metabolic syndrome, Bardet-Biedel syndrome, Prader-Willi syndrome, tuberous sclerosis, Albright hereditary osteodystrophy, brain-derived neurotrophic factor (BDNF) deficiency; Single-minded 1 (SIM1) deficiency, leptin deficiency, leptin receptor deficiency, pro-opiomelanocortin (POMC) defects, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, Src homology 2B 1 (SH2B 1) deficiency, pro-hormone convertase ⅓ deficiency, melanocortin-4-receptor (MC4R) deficiency, Wilms tumor, aniridia, genitourinary anomalies, mental retardation (WAGR) syndrome, pseudohypoparathyroidism type 1A, Fragile X syndrome, Borjeson-Forsmann-Lehmann syndrome, Alstrom syndrome, Cohen syndrome and ulnar-mammary syndrome, and said target molecule is a gut barrier enhancer molecule or a satiety effector molecule. In that embodiment, said heterologous or engineered nucleic acid is typically a gene or gene cassette for producing a gut barrier enhancer molecule, a gene or gene cassette for producing a satiety effector molecule, or encodes one or more enzymes present in a biosynthetic pathway for producing a short chain fatty acid, e.g. , butyrate, propionate, and/or acetate.
In another particular embodiment, said method is for treating and/or preventing a metabolic disease, such as obesity or type 2 diabetes, and said target molecule is a metabolic or satiety effector molecule, preferably selected from the group consisting of n-acyl-phosphatidylethanolamine (NAPE), a n-acyl-ethanolamines (NAE), a ghrelin receptor antagonist, peptide YY3- 36, a cholecystokinin (CCK), CCK58, CCK33, CCK22, CCK8, a bombesin, gastrin releasing peptide (GRP), neuromedin B (P), glucagon, GLP-1, GLP-2, apolipoprotein A-IV, amylin, somatostatin, enterostatin, oxyntomodulin, pancreatic peptide, a short-chain fatty acid, butyrate, propionate, acetate, a serotonin receptor agonist, nicotinamide adenine dinucleotide (NAD), nicotinamide mononucleotide (NMN), nucleotide riboside (NR), nicotinamide, and nicotinic acid (NA), and/or tryptophan metabolite. In that embodiment, said heterologous or engineered nucleic acid typically encodes a tryptophan transporter, an enzyme metabolizing tryptophan, an enzyme for producing a tryptophan metabolite, an enzyme for producing kynurenine, an enzyme for producing kynurenic acid, an enzyme for producing an indole, an enzyme for producing indole-3 -acetic acid, or any of the above target molecules.
In another particular embodiment, said method is for treating and/or preventing a cancer, typically selected from adrenal cancer, adrenocortical carcinoma, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer (e.g., Ewing sarcoma tumors, osteosarcoma, malignant fibrous histiocytoma), brain cancer (e.g., astrocytomas, brain stem glioma, craniopharyngioma, ependymoma), bronchial tumors, central nervous system tumors, breast cancer, Castleman disease, cervical cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gestational trophoblastic disease, heart cancer, Kaposi sarcoma, kidney cancer, largyngeal cancer, hypopharyngeal cancer, leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia), liver cancer, lung cancer, lymphoma (e.g., AIDS-related lymphoma, Burkitt lymphoma, cutaneous T cell lymphoma, Hogkin lymphoma, Non-Hogkin lymphoma, primary central nervous system lymphoma), malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity cancer, paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, rhabdoid tumor, salivary gland cancer, sarcoma, skin cancer (e.g., basal cell carcinoma, melanoma), small intestine cancer, stomach cancer, teratoid tumor, testicular cancer, throat cancer, thymus cancer, thyroid cancer, unusual childhood cancers, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macrogloblulinemia, and Wilms tumor; and said target molecule is an anti-cancer molecule. In that embodiment, said heterologous or engineered nucleic is typically a gene sequence(s) or gene set for producing one or more anti-cancer molecule(s) such as one or more immune checkpoint inhibitor(s) (in particular selected from a CTLA-4 inhibitor, a PD-1 inhibitor, and a PD-L1 inhibitor), an immune checkpoint inhibitor of TIGIT, VISTA, LAG-3, TIM1, CEACAM1, LAIR-1, HVEM, BTLA, CD160, CD200, CD200R, GITR, or A2aR, IL-15, IL-12, IL-2, GM-CSF, IL-21, an agonist ligand for OX40, an agonist ligand for ICOS, kynureninase, arginine, a cytotoxin or a lytic peptide.
In a particular embodiment, the method of the invention is for improving menopause symptoms. In such embodiment, said engineered bacterial strain preferably comprises at least one heterologous nucleic acid encoding a daidzein-metabolizing enzyme, more particularly at least one heterologous nucleic acid encoding a daidzein-to-dihydrodaidzein (DHD)-converting enzyme and/or at least one heterologous nucleic acid encoding a DHD-to-equol-converting enzyme. In a more particular embodiment, said engineered bacterial strain comprises at least one heterologous nucleic acid selected from the group consisting of the orf-1 and orf-2 genes from Slackia sp. strain NATTS (as disclosed in Tsuji et al. (2012) Appl Environ Microbiol. 78(4): 1228-1236), and/or at least one heterologous nucleic acid which is the orf-3 gene from Slackia sp. strain NATTS (as disclosed in Tsuji et al. (2012) Appl Environ Microbiol. 78(4): 1228-1236).
In another particular embodiment, the method of the invention is for improving gluten intolerance.
In another particular embodiment, the method of the invention is for improving lactose intolerance.
In another particular embodiment, the method of the invention is for decreasing microbiome-induced irinotecan toxicity.
In another particular embodiment, the method of the invention is for treating and/or preventing phenylketonuria (PKU).
In another particular embodiment, the method of the invention is for treating and/or preventing enteric hyperoxaluria.
In the context of the invention, examples of diseases, disorders or conditions to be treated or prevented by the method of the invention include a neurodegenerative disease or condition; a brain disease or condition; a CNS disease or condition; memory loss or impairment; a heart or cardiovascular disease or condition, such as heart attack, stroke or atrial fibrillation; a liver disease or condition; a kidney disease or condition, such as chronic kidney disease (CKD); a pancreas disease or condition; a lung disease or condition, such as cystic fibrosis or COPD; a gastrointestinal disease or condition; a throat or oral cavity disease or condition; an ocular disease or condition; a genital disease or condition, such as a vaginal, labial, penile or scrotal disease or condition; a sexually-transmissible disease or condition, such as gonorrhea, HIV infection, syphilis or chlamydia infection; an ear disease or condition; a skin disease or condition; a heart disease or condition; a nasal disease or condition; a haematological disease or condition, such as anaemia, in particular anaemia of chronic disease or cancer; a viral infection; a pathogenic bacterial infection; a cancer; an autoimmune disease or condition, such as SLE; an inflammatory disease or condition, such as rheumatoid arthritis, psoriasis, eczema, asthma, ulcerative colitis, colitis, Crohn’s disease or IBD; autism; ADHD; bipolar disorder; ALS (Amyotrophic Lateral Sclerosis); osteoarthritis; a congenital or development defect or condition; miscarriage; a blood clotting condition; bronchitis; dry or wet AMD; neovascularisation (for example of a tumour or in the eye); common cold; epilepsy; fibrosis, such as, liver or lung fibrosis; a fungal disease or condition, such as thrush; a metabolic disease or condition, such as obesity, anorexia, diabetes, Type I or Type II diabetes; ulcer(s), such as gastric ulceration or skin ulceration; dry skin; Sjogren’s syndrome; cytokine storm; deafness, hearing loss or impairment; slow or fast metabolism (ie, slower or faster than average for the weight, sex and age of the subject); conception disorder, such as infertility or low fertility; jaundice; skin rash; Kawasaki disease; Lyme disease; an allergy, such as a nut, grass, pollen, dust mite, cat or dog fur or dander allergy; malaria, typhoid fever, tuberculosis or cholera; depression; mental retardation; microcephaly; malnutrition; conjunctivitis; pneumonia; pulmonary embolism; pulmonary hypertension; a bone disorder; sepsis or septic shock; sinusitus; stress (such as occupational stress); thalassaemia, anaemia, von Willebrand Disease, or haemophilia; Shingles or cold sore; menstruation; and low sperm count.
In an example, the neurodegenerative or CNS disease, disorder or condition is selected from the group consisting of Alzheimer disease, geriopsychosis, Down syndrome, Parkinson’s disease, Creutzfeldt-Jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington’s disease, Machado-Joseph disease, amyotrophic lateral sclerosis and diabetic neuropathy.
Autoimmune diseases that may be treated or prevented include Acute Disseminated Encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease, Meniere’s disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic’s), neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonage-Turner syndrome, Pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, Tolosa-Hunt syndrome, transverse myelitis, Type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, and Wegener’s granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).
Inflammatory diseases that may be treated or prevented include Alzheimer disease, ankylosing spondylitis, arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), asthma, atherosclerosis, Crohn’s disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson’s disease, and ulcerative colitis.
In the context of the invention, the term “treating” or “treatment” means reversing, alleviating, or inhibiting the progress of the disease, disorder or condition to which such term applies, or one or more symptoms of such disease, disorder or condition.
In the context of the invention, the term “prevention” refers to any indicia of success in protecting a subject or patient (e.g. a subject or patient at risk of developing a disease, disorder or condition) from developing, contracting, or having a disease, disorder or condition, including preventing one or more symptoms of a disease, disorder or condition or diminishing the occurrence, severity, or duration of any symptoms of a disease, disorder or condition following administration of the engineered bacterial strain as described herein.
By a “therapeutically effective amount” of an engineered bacterial strain of the invention and rare carbohydrate is meant a sufficient amount of the engineered bacterial strain and the rare carbohydrate to treat a specific disease, disorder or condition, to contribute to the treatment of a specific disease, disorder or condition, or to avoid side effects of a treatment of a specific disease, disorder or condition, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the engineered bacterial strain of the present invention and rare carbohydrate will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disease, disorder or condition being treating and the severity of the disease, disorder or condition, activity of the specific engineered bacterial strain and rare carbohydrate employed, the specific combinations employed, the age, body weight, general health, sex and diet of the subject, the time of administration, route of administration and rate of excretion of the specific engineered bacterial strains and rare carbohydrate employed, the duration of the treatment, drugs used in combination or coincidental with the specific engineered bacterial strains and rare carbohydrate employed, and like factors well known in the medical arts.
The present invention also concerns a method for the cosmetic caring of a subject presenting an unesthetic manifestation due to a target molecule, said method comprising
The present invention also concerns a method for the cosmetic caring of a subject presenting an unesthetic manifestation which can be treated by a target molecule, said method comprising
By “unesthetic manifestation” is meant herein a non-pathological manifestation on a subject, in particular on the skin of a subject, of the effect of a particular molecule on the subject. Examples of unesthetic manifestation include redness, feeling of heat or warmth, tension, tingling, stinging, tightness, pigment spots, burning sensation, itching sensation, tautness, visible squama, thickening of the skin, wrinkles, sagging skin, localized resistant fat, and/or cellulite appearance.
In both cosmetic methods, the engineered bacterial strain becomes present in the microbiome of said subject at a colonization level enabling an overall production of the molecule of interest in an amount efficient for modulating the level of or modifying the target molecule at a rate leading to a cosmetic effect on said subject.
The methods of the invention of modulating the level of or modifying a target molecule can also be applied to the environment.
For example, the method of the invention can be applied to soil or water to eliminate a toxin or environmental contamination, such as in an industrial chemical spill or waste product. The method of the invention can also be applied to waste water or industrial waste or byproduct to decontaminate or detoxify the waste. In yet other embodiments, the method of the invention can be applied to industrial or environmental material such as but not limited to agricultural or food production waste to produce or improve the production of a metabolic product.
The present invention also concerns an engineered bacterial strain, as defined above, comprising a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, as defined above, and a heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate, as defined above.
In particular embodiments, the engineered bacterial strain of the invention is in a pharmaceutical, veterinary or cosmetic composition.
The pharmaceutical or veterinary composition according to the invention may further comprise a pharmaceutically acceptable excipient.
By “pharmaceutically acceptable excipient” is meant herein a non-pharmaceutically active additive used in the manufacture of a pharmaceutical composition, which allows the pharmaceutically active ingredient to be manufactured into a pharmaceutical formulation or a galenic formulation providing the necessary bioavailability of the medicament to the patient upon the administration of the pharmaceutical composition. The excipient is preferably compatible with the other ingredients of the composition and produces no adverse effect, allergic reaction or other undesirable reaction when it is administered to a human or an animal.
The cosmetic composition according to the invention may further comprise a cosmetically acceptable excipient.
By “cosmetically acceptable excipient” is meant herein a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a cosmetic composition or otherwise used as a vehicle, carrier, or diluents to facilitate administration of a cosmetically active ingredient and that is compatible therewith.
A solid pharmaceutically or cosmetically acceptable vehicle or excipient may include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet- disintegrating agents. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
The pharmaceutical, veterinary or cosmetic composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. The pharmaceutical, veterinary or cosmetic compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monooleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The engineered bacterial strain according to the invention can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for enteral administration include sterile solutions, emulsions, and suspensions.
The engineered bacterial strain according to the invention may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical or cosmetic additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration. The liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
In some embodiments, the invention encompasses pharmaceutical, veterinary or cosmetic composition formulated for delayed or gradual enteric release. In preferred embodiments, formulations or pharmaceutical preparations of the invention are formulated for delivery of the engineered bacterial strain into the distal small bowel and/or the colon. The formulation can allow the engineered bacterial strain to pass through stomach acid and pancreatic enzymes and bile, and reach undamaged to be viable in the distal small bowel and colon.
In some embodiments, the pharmaceutical, veterinary or cosmetic composition is micro-encapsulated, formed into tablets and/or placed into capsules, preferably enteric-coated capsules.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release, using cellulose acetate (CA) and polyethylene glycol (PEG). In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a hydroxypropylmethylcellulose (HPMC), a microcrystalline cellulose (MCC) and magnesium stearate. In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using e.g., a poly(meth)acrylate, e.g. a methacrylic acid copolymer B, a methyl methacrylate and/or a methacrylic acid ester, or a polyvinylpyrrolidone (PVP).
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a release-retarding matrix material such as: an acrylic polymer, a cellulose, a wax, a fatty acid, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, polyvinylpyrrolidone, a vinyl acetate copolymer, a vinyl alcohol copolymer, polyethylene oxide, an acrylic acid and methacrylic acid copolymer, a methyl methacrylate copolymer, an ethoxyethyl methacrylate polymer, a cyanoethyl methacrylate polymer, an aminoalkyl methacrylate copolymer, a poly(acrylic acid), a poly(methacrylic acid), a methacrylic acid alkylamide copolymer, a poly(methyl methacrylate), a poly(methacrylic acid anhydride), a methyl methacrylate polymer, a polymethacrylate, a poly(methyl methacrylate) copolymer, a polyacrylamide, an aminoalkyl methacrylate copolymer, a glycidyl methacrylate copolymer, a methyl cellulose, an ethylcellulose, a carboxymethylcellulose, a hydroxypropylmethylcellulose, a hydroxymethyl cellulose, a hydroxyethyl cellulose, a hydroxypropyl cellulose, a crosslinked sodium carboxymethylcellulose, a crosslinked hydroxypropylcellulose, a natural wax, a synthetic wax, a fatty alcohol, a fatty acid, a fatty acid ester, a fatty acid glyceride, a hydrogenated fat, a hydrocarbon wax, stearic acid, stearyl alcohol, beeswax, glycowax, castor wax, carnauba wax, a polylactic acid, polyglycolic acid, a co-polymer of lactic and glycolic acid, carboxymethyl starch, potassium methacrylate/divinylbenzene copolymer, crosslinked polyvinylpyrrolidone, polyvinylalcohols, polyvinylalcohol copolymers, polyethylene glycols, non-crosslinked polyvinylpyrrolidone, polyvinyl acetates, polyvinylacetate copolymers or any combination thereof.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release as described in U.S. Pat. App. Pub. 20110218216, which describes an extended release pharmaceutical composition for oral administration, and uses a hydrophilic polymer, a hydrophobic material and a hydrophobic polymer or a mixture thereof, with a microenvironment pH modifier. The hydrophobic polymer can be ethylcellulose, cellulose acetate, cellulose propionate, cellulose butyrate, methacrylic acid-acrylic acid copolymers or a mixture thereof. The hydrophilic polymer can be polyvinylpyrrolidone, hydroxypropylcellulose, methylcellulose, hydroxypropylmethyl cellulose, polyethylene oxide, acrylic acid copolymers or a mixture thereof. The hydrophobic material can be a hydrogenated vegetable oil, hydrogenated castor oil, carnauba wax, candelilla wax, beeswax, paraffin wax, stearic acid, glyceryl behenate, cetyl alcohol, cetostearyl alcohol or and a mixture thereof. The microenvironment pH modifier can be an inorganic acid, an amino acid, an organic acid or a mixture thereof. Alternatively, the microenvironment pH modifier can be lauric acid, myristic acid, acetic acid, benzoic acid, palmitic acid, stearic acid, oxalic acid, malonic acid, succinic acid, adipic acid, sebacic acid, fumaric acid, maleic acid; glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, sodium dihydrogen citrate, gluconic acid, a salicylic acid, tosylic acid, mesylic acid or malic acid or a mixture thereof.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are a powder that can be included into a tablet or a suppository. In alternative embodiments, a formulation or pharmaceutical preparation of the invention can be a “powder for reconstitution” as a liquid to be drunk or otherwise administered.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can be administered in a cream, gel, lotion, liquid, feed, or aerosol spray. Engineered bacterial strains may be immobilized onto appropriately sized polymeric beads so that the coated beads may be added to aerosols, creams, gels or liquids. The size of the polymeric beads may be from about 0.1 µm to 500 µm, for example 50 µm to 100 µm. The coated polymeric beads may be incorporated into animal feed, including pelleted feed and feed in any other format, incorporated into any other edible device used to present phage to the animals, added to water offered to animals in a bowl, presented to animals through water feeding systems. In some embodiments, the compositions are used for treatment of surface wounds and other surface infections using creams, gels, aerosol sprays and the like.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can be administered by inhalation, in the form of a suppository or pessary, topically (e.g., in the form of a lotion, solution, cream, ointment or dusting powder), epi- or transdermally (e.g., by use of a skin patch), orally (e.g., as a tablet, which may contain excipients such as starch or lactose), as a capsule, ovule, elixirs, solutions, or suspensions (each optionally containing flavoring, coloring agents and/or excipients), or they can be injected parenterally (e.g., intravenously, intramuscularly or subcutaneously). For parenteral administration, the compositions may be used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can also be dermally or transdermally administered. For topical application to the skin, the pharmaceutical, veterinary or cosmetic composition can be combined with one or a combination of carriers, which can include but are not limited to, an aqueous liquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, proteins carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof. A topical mode of delivery may include a smear, a spray, a bandage, a time-release patch, a liquid-absorbed wipe, and combinations thereof. The pharmaceutical, veterinary or cosmetic composition can be applied to a patch, wipe, bandage, etc., either directly or in a carrier(s). The patches, wipes, bandages, etc., may be damp or dry, wherein the engineered bacterial strain is in a lyophilized form on the patch. The carriers of topical compositions may comprise semi-solid and gel-like vehicles that include a polymer thickener, water, preservatives, active surfactants, or emulsifiers, antioxidants, sun screens, and a solvent or mixed solvent system. U.S. Pat. No. 5,863,560 discloses a number of different carrier combinations that can aid in the exposure of skin to a medicament, and its contents are incorporated herein.
For intranasal or administration by inhalation, the pharmaceutical, veterinary or cosmetic composition is conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, or nebuliser with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container, pump, spray, or nebuliser may contain a solution or suspension of the active compound, e.g., using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g., sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the engineered bacterial strain of the invention and a suitable powder base such as lactose or starch.
For administration in the form of a suppository or pessary, the pharmaceutical, veterinary or cosmetic composition can be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment, or dusting powder. Compositions of the invention may also be administered by the ocular route. For ophthalmic use, the compositions of the invention can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
Dosages and desired drug concentrations of the pharmaceutical and veterinary composition compositions of the present invention may vary depending on the particular use. The determination of the appropriate dosage or route of administration is within the skill of an ordinary physician. Animal experiments can provide reliable guidance for the determination of effective doses in human therapy.
For transdermal administration, the pharmaceutical, veterinary or cosmetic composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
For transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used. The active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
The subject according to the invention is an animal, preferably a mammal, even more preferably a human. However, the term “subject” can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs and non-human primates, among others, or non-mammals such as poultry, that are in need of treatment.
The human subject according to the invention may be a human at the prenatal stage, a newborn, a child, an infant, an adolescent or an adult at any age. Preferably, the subject is an adult at any age.
In a preferred embodiment, the subject has been diagnosed with, or is at risk of developing a disease, disorder or condition due to or associated with the target molecule or a disease, disorder or condition the treatment of which can be due to or associated with the target molecule. Diagnostic methods of such disease, disorder or condition are well known by the man skilled in the art.
In a particular embodiment, the disease, disorder or condition presents a resistance to known treatments.
In a particular embodiment, the subject has never received any treatment prior to the administration of the engineered bacterial strain according to the invention.
In a particular embodiment, the subject has already received at least one line of treatment, preferably several lines of treatment, prior to the administration of the engineered bacterial strain according to the invention.
Preferably, the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day. In a particular embodiment, the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day.
The duration of treatment according to the invention is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, still more preferably between 1 day and 4 weeks, even more preferably between 1 day and 2 weeks. In a particular embodiment, the duration of the treatment is about 1 week. Alternatively, the treatment may last as long as the disorder and/or disease persists.
In a particular embodiment, the duration of treatment according to the invention is comprised between 2 days and 20 weeks and involves (i) several successive administrations of the engineered bacterial strain and of the rare carbohydrate, or (ii) a single administration of the engineered bacterial strain and several successive administrations of the rare carbohydrate, or (iii) several successive administrations of the engineered bacterial strain and several successive administrations of the rare carbohydrate, the administrations of the rare carbohydrate being continued at least once after stopping administrations of the engineered bacterial strain.
The form of the pharmaceutical or veterinary compositions comprising the engineered bacterial strain of the invention and/or the rare carbohydrate, the route of administration and the dose of administration thereof can be adjusted by the man skilled in the art according to the type and severity of the disease or disorder (e.g. depending on the target molecule involved in the disease or disorder and its localization in the patient’s or subject’s body), and to the patient or subject, in particular its age, weight, sex, and general physical condition.
Particularly, the amount of engineered bacterial strains according to the invention and/or the amount of rare carbohydrate, to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient or subject (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient or subject.
For example, the total amount of engineered bacterial strain, for each administration may be comprised between 1 billion and 100 billion cfu of engineered bacteria, from 5 billion to 50 billion cfu, or from 10 billion to 25 billion cfu of engineered bacteria.
For example, when the rare carbohydrate is milk oligosaccharide, the total amount of milk oligosaccharide, for each administration, may be comprised between 4.5 and 18 g of milk oligosaccharide per day, in particular between 9 and 18 g of milk oligosaccharide per day.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
All publications mentioned herein are incorporated herein by reference. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.
It must be noted that as used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells (e.g., a population of such cells). Similarly, reference to “a nucleic acid” includes one or more of such nucleic acids.
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bacteroides plebeius
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Bifidobacterium longum subsp. infantis
Phenylketonuria (PKU) is a rare disease caused by biallelic mutations in the PAH gene of patient cells that result in an inability to convert phenylalanine (Phe) to tyrosine, elevated blood Phe levels and severe neurological complications if untreated. Most patients are unable to adhere to the protein-restricted diet, and thus have a high Phe level in the gut and do not achieve target blood Phe levels.
A P. freudenreichii strain is genetically engineered to comprise (i) the genes encoding phenylalanine ammonia lyase and L-amino acid deaminase, which allow for bacterial consumption of Phe within the gastrointestinal tract, and therefore reduction of blood Phe level in the subject, and (ii) the 2’FL transporter gene that confers a competitive advantage to this strain in the subject’s microbiome once administered orally to the patient together with 2’FL.
Natural evolution is a destructive force for synthetic biology, a force that can act counter to engineered constructs in an attempt to rid the organism of any costly unessential processes. To increase the chances that the genes encoding functional phenylalanine ammonia lyase and L-amino acid deaminase stably remains in the engineered P. freudenreichii strain, the expression of these genes which drive unessential processes for the bacteria itself is directly coupled to the expression of the 2’FL transporter gene which on the contrary provides a strong competitive advantage to the bacteria. To achieve this, the three genes are engineered so as to be part of a single operon, with the 2’FL transporter gene placed as the last gene of the operon.
This system ensures that bacteria in which a frameshift mutation and/or a point mutation leading to a STOP codon takes place in the transgene, would lose their competitive advantage among not not only the subject’s natural microbiome but also among the rest of the other engineered P. freudenreichii strains administered to the patients in which functional genes encoding phenylalanine ammonia lyase and L-amino acid deaminase remain.
This application claims the benefit of U.S. Provisional Application 63/253,246, filed on Oct. 7, 2021, the contents of which is incorporated herein by reference in its entirety for all purposes.
| Number | Date | Country | |
|---|---|---|---|
| 63253246 | Oct 2021 | US |
